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Abstract 
Size exclusion PEGylation reaction chromatography was investigated using a model 
developed by Fee (2005).  Column dispersion was neglected and the PEGylation 
reaction was modelled as second order.  The model allowed up to four PEG groups to 
be attached to a protein and accounted for succinic acid hydrolysis from activated 
PEG.  The model was adapted to simulate α-lactalbumin PEGylation and succinic 
acid hydrolysis from activated PEG in a batch stirred tank so rate parameters from 
stirred tank kinetic experiments could be obtained and the model verified.  The model 
was solved using finite differences and simulations run in Matlab.  The effect of 
reaction parameters such as timing, length and concentration of PEG and protein 
injection, reaction rates, and model resolution on model simulation results was 
explored. 
 
In the size exclusion PEGylation simulations it was found that increasing protein 
concentration increased MonoPEG concentrations and increased the ratio of 
MonoPEG to starting protein feed concentration.  Increasing PEG pulse length and 
starting PEG concentration initially increased MonoPEG concentration and product 
ratio until all protein had been PEGylated at which point MonoPEG concentration the 
product ratio levelled out.  Increasing PEG hydrolysis rates did not affect the amount 
of MonoPEG produced but reduced the activated PEG concentration and increased 
succinic acid concentration.  Optimal conditions for producing MonoPEG were found 
to be equal concentrations of PEG and protein, with the PEG injection length twice as 
long as the protein injection, and the PEG injection done immediately after the protein 
injection. 
iii 
Acknowledgements 
 
I would like to thank my supervisors, Professor Conan Fee and Dr. Mark Lay, for 
their direction, assistance and guidance. In particular, Prof. Conan Fee’s 
recommendations and suggestions have been invaluable for this project. I also wish to 
thank Dr. Mark Lay, who has taught me some programming and writing techniques. 
Thanks are also due to Mary Dalbeth our department secretary and Lisa Li the 
department technician for their excellent services and assistance. Thanks to Prof. Janis 
Swan for her support and extremely valuable tips of survival,.when I came to this 
university as an international student. Special thanks to be given to my student 
colleagues Amita Chand and Yuewen Lin for their entertaining tea-room 
conversations and support. Thanks to the international student’s advisor, Stephen 
Harte, for his valuable advice on finding accommodation and buying a second hand 
car. Thanks to all my flat-mates, namely Abhinandan Rao, Xu Su and Ameya Vaidya 
for their cooperation, cheerful encouragement and extra-curricular activities. The 
supervisors at Digipoll, namely Nikki Henderson, Shelly Karaka, Candice Duke and 
Gill for providing this poor student with plenty of job. I also need to thank Gordon 
Rajendram for providing this poor student with accommodation and plenty of jobs to 
do. Words alone cannot express the thanks I owe to Angela Cosgrove for giving me 
encouragement and love.  
 
The Sanghvi and Patel families who kept inviting me to their place on weekends to 
make sure I was not missing the homely environment and also provided me with 
many tasty meals. Thanks to Dr. Guna Magesan for introducing me to the Hindu 
Swayam Sevak Sangh, the voluntary organisation. 
 
And last but not least, my beloved family, without whom it would not have been 
possible for me to achieve the quality education in New Zealand, helped me achieve 
every aim in my life and did all the good things that good parents do. 
 
iv 
Contents 
 
Abstract.........................................................................................................................ii 
Acknowledgements .................................................................................................... iii 
Contents .......................................................................................................................iv 
List of Figures.............................................................................................................vii 
List of Tables ...............................................................................................................ix 
Nomenclature ...............................................................................................................x 
CHAPTER 1: INTRODUCTION .........................................................................................1 
1.1 Background ....................................................................................................2 
1.2 Research objective .........................................................................................3 
1.3 Organization of this thesis .............................................................................4 
CHAPTER 2: LITERATURE REVIEW ..............................................................................5 
2.1 Introduction....................................................................................................6 
2.2 Properties of PEG ..........................................................................................7 
2.3 Improved protein drugs by PEGylation .........................................................9 
2.4 PEGylation chemistry ..................................................................................10 
2.4.1 Amino group modification...................................................................11 
2.4.2 Thiol modification ...............................................................................13 
2.4.3 Site specific modification ....................................................................15 
2.4.4 Reversible PEGylation.........................................................................16 
2.5 Factors affecting PEGylated conjugate behaviour.......................................17 
2.5.1 Site of conjugation and number of polymers attached.........................17 
2.5.2 Size of PEG..........................................................................................19 
2.5.3 Stabilizing agents .................................................................................20 
2.5.4 Molecular flexibility ............................................................................20 
2.5.5 Conditions affecting PEGylation reactions..........................................21 
2.6 Limitations and drawbacks in the use of PEG.............................................22 
2.7 Batch PEGylation.........................................................................................23 
2.8 Packed bed process ......................................................................................24 
2.9 Purification engineering...............................................................................25 
2.9.1 Size-based separations .........................................................................27 
v 
2.9.2 Charged-based separations...................................................................28 
2.10 FDA approved PEGylated drugs .................................................................29 
2.11 Other applications ........................................................................................30 
2.12 Conclusion ...................................................................................................34 
CHAPTER 3:  MODELLING ...........................................................................................35 
3.1 Introduction..................................................................................................36 
3.2 PEGylation reaction .....................................................................................37 
3.3 PEGylation reaction in an axial flow size exclusion column ......................39 
3.3.1 Finite difference solution for axial flow size exclusion column 
chromatography ...................................................................................................41 
3.3.2 Stirred tank rate kinetic experiments ...................................................47 
3.4 Conclusion ...................................................................................................48 
CHAPTER 4: METHODOLOGY......................................................................................49 
4.1 Introduction..................................................................................................50 
4.2 Reagents.......................................................................................................50 
4.3 Equipment ....................................................................................................51 
4.4 Batch kinetics...............................................................................................51 
4.4.1 Succinic acid hydrolysis from activated PEG......................................51 
4.4.2 Batch PEGylation.................................................................................52 
4.5 Column calibration.......................................................................................53 
CHAPTER 5: RESULTS AND DISCUSSION .....................................................................54 
5.1 Introduction..................................................................................................55 
5.2 Batch PEG hydrolysis ..................................................................................55 
5.2.1 Calculations for the mass of succinic acid...........................................59 
5.2.2 Model parameters for succinic acid hydrolysis from PEG ..................61 
5.3 Rate kinetics for PEGylation reaction..........................................................62 
5.4 Evaluation of results obtained from MatLab simulations............................68 
5.4.1 Batch model .........................................................................................68 
5.4.2 Axial flow size exclusion reaction model ............................................70 
Varied protein concentration............................................................................72 
Increasing PEG pulse.......................................................................................75 
Rate of hydrolysis of PEG ...............................................................................80 
Product mass and ratio .....................................................................................82 
5.4.3 Sample simulation curves ....................................................................82 
vi 
1. Sample curve................................................................................................82 
2. Variation of PEG pulse ................................................................................83 
3. Change in concentration ..............................................................................84 
4. Change in time step......................................................................................85 
5. Change in k value.........................................................................................87 
6. Change in rate of hydrolysis of PEG ...........................................................88 
7. Change in resolution ....................................................................................90 
5.4.4 Discussion from simulation .................................................................91 
CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS..............................................94 
6.1 General findings...........................................................................................95 
6.2 Recommendations for future work ..............................................................97 
References ...................................................................................................................98 
Appendix A:  Matlab models ..................................................................................105 
A.1  Axial flow size exclusion reaction column................................................105 
A.2   Continuous stirred batch model .................................................................111 
Appendix B:  Raw Results.......................................................................................114 
vii 
List of Figures 
Figure 2- 1: PEGylated protein .....................................................................................7 
Figure 2- 2: Chemical structures of some representative polyethylene glycol (PEG) 
molecules (Bailon and Berthold 1998). .........................................................................8 
Figure 2- 3 Alkylation of PEG-aldehyde (Veronese 2001) ........................................11 
Figure 2- 4 Activated alkyl acids (Veronese 2001) ....................................................12 
Figure 2- 5: PEG-p-nitrophenlcarbonate and PEG-trichlorophenylcarbonate 
(Veronese 2001)...........................................................................................................12 
Figure 2- 6 Thiol reactive PEG-orthopyridyl-disulphide (Veronese 2001) ................13 
Figure 2- 7 Reversible PEGylation .............................................................................16 
Figure 2- 8: Overlapping bioactivities of components of a polyethylene glycol (PEG) 
conjugate mixture (Bailon and Berthold 1998). ..........................................................18 
Figure 2- 9: In vitro and in vivo biological activities as a function of polyethylene 
glycol (PEG) mass (Bailon and Berthold 1998). .........................................................19 
Figure 2- 10: Rigid Linear Molecule and Flexible Linear Molecule..........................21 
Figure 2- 11:  Histological analysis of transplanted islets (A) unmodified islets 
rejected within 2 weeks, (B) PEGylated islets rejected at day 30, (C, D) PEGylated 
islets survived for 100 days (Lee et al 2006) ...............................................................32 
Figure 3- 1: Axial flow model.....................................................................................43 
Figure 5- 1: hydrolysis of 2kDa linear PEG ...............................................................56 
Figure 5- 2: hydrolysis of 20kDa branched PEG........................................................57 
Figure 5- 3:  PEGylated and native a-lactalbumin concentrations with time in batch 
PEGylation reaction (Li 2004).....................................................................................63 
Figure 5- 4: MonoPEG formation against time (say what those symbols are) Test for 
second order kinetics....................................................................................................64 
Figure 5- 5: Ditto Test for second order kinetics, fit is satisfactory ...........................65 
Figure 5- 6: Reaction rate of MonoPEG Solid line represents model where as points 
represent experimental data.  Where, CM= concentration of monoPEG ....................67 
Figure 5- 7:  mass of the reaction components and percentage of protein converted at 
differing mass of PEG..................................................................................................70 
Figure 5- 8: product mass vs protein concentration (mg/ml)......................................74 
Figure 5- 9: product ratio vs. protein concentration (mg/ml) .....................................74 
Figure 5- 10: product mass vs pulse length of PEG (CPEG= 10mg/mL) .....................76 
viii 
Figure 5- 11: product mass vs pulse length of PEG (CPEG= 20mg/mL) .....................77 
Figure 5- 12: product ratio vs PEG pulse length (CPEG= 10mg/mL) ..........................77 
Figure 5- 13: product ratio vs pulse length of PEG (CPEG= 20mg/mL)......................78 
Figure 5- 14: product mass vs pulse length of PEG (CPEG= 40mg/mL) .....................79 
Figure 5- 15: product ratio vs pulse length (CPEG= 40mg/mL)...................................79 
Figure 5- 16:  product mass vs k hydrolysis ...............................................................81 
Figure 5- 17: product ratio vs k hydrolysis .................................................................81 
Figure 5- 18: sample curve for the simulation of axial flow size exclusion model ....83 
Figure 5- 19: variation of PEG pulse length ...............................................................84 
Figure 5- 20:  change in concentration of PEG...........................................................85 
Figure 5- 21: Change in time steps at J =5..................................................................86 
Figure 5- 22: Change in time steps at J =1..................................................................86 
Figure 5- 23: change in rater of reaction of protein ....................................................88 
Figure 5- 24: change in rate of hydrolysis of PEG .....................................................89 
Figure 5- 25: change in resolution at X=round(L./(64.*Dp)) .....................................90 
Figure 5- 26: change in resolution at X=round(L./(8.*Dp)) .......................................91 
Figure 5- 27: Example for the suggested method for PEGylation..............................93 
 
ix 
List of Tables 
Table 2- 1: PEGs reactive towards thiol group (Veronese and Pasut 2005) ...............14 
Table 2- 2: Approved PEG conjugates (Veronese and Pasut 2005) ...........................31 
Table 5- 1: Results for the hydrolysis of 2kDa linear PEG.........................................57 
Table 5- 2: Results for the hydrolysis of 20kDa branched PEG .................................58 
Table 5- 3: Calculated mass for 2kDa PEG ................................................................58 
Table 5- 4: Calculated mass for 20kDa PEG ..............................................................59 
Table 5- 5: The values obtained from the unpublished work by Li (2004) ................62 
Table 5- 6: The experimental data and the model values............................................64 
Table 5- 7: Mass balance at k= 0 mL/mg.s .................................................................71 
Table 5- 8: Mass balance at Cprotein = 0 mg/mL ..........................................................72 
Table 5- 9: The concentration and the mass of protein used for simulations..............73 
Table 5- 10: The pulse length and the mass of PEG used for simulations..................76 
Table 5- 11: The pulse length and the mass of PEG used for simulations..................78 
Table 5- 12: Mass of reaction components at pulse length of PEG= 20 min..............92 
Table B- 1: results of simulation by varying the concentration of proteins 114 
Table B- 2: product ratio of components at varied concentration of proteins...........115 
Table B- 3: results of simulations at different PEG pulse length (CPEG= 10mg/mL)115 
Table B- 4: results of simulations at different PEG pulse length (CPEG= 20mg/mL)116 
Table B- 5: product ratios at different PEG pulse length (CPEG= 10mg/mL) ...........116 
Table B- 6: product ratios at different PEG pulse length (CPEG= 20mg/mL) ...........116 
Table B- 7: results of simulations at different PEG pulse length (CPEG= CProtein= 
40mg/mL) ..................................................................................................................117 
Table B- 8: product ratios at different PEG pulse length (CPEG= 40mg/mL) ...........117 
Table B- 9: results of simulations at different k hydrolysis ......................................118 
Table B- 10: product ratios at different k hydrolysis of PEG ...................................118 
x 
Nomenclature 
 
Ac   Cross sectional area (cm2) 
AC    Solution concentration of solute A in solution (mg/ml) 
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dp   Resin particle diameter (cm) 
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2k    PEGylation reaction rate for monoPEG (ml/mg.s) 
hydrk    Hydrolysis rate for activated PEG (1/s) 
( )nk  PEGylation reaction rate (ml/mg.s) 
aviK    Available pore and interstitial volume fraction (cm/s) 
xi 
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n    Stage number (dimensionless) 
N   Total number of stages (dimensionless) 
Q    Volumetric flow rate of solution through the column (ml/s) 
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monoPEGr   Rate of reaction of monoPEG (mg/mls) 
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PEGstartt  Time at which PEG is introduced to column (s) (or in time 
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T   Total time steps (s) 
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Ve   Volume of each stage (ml) 
Vi   Volume applied for jth step (ml) 
x   Distance through column (cm or steps) 
X   Number of stages (dimensionless) 
 
Greek  
 
ε    Packed bed interstitial void fraction (dimensionless) 
pi    Constant (3.142) 
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Introduction  2 
 
1.1 Background 
Advances in biochemistry, genetics and biotechnology has led to the proliferation of 
biologically derived pharmaceuticals and therapeutics.  These are routinely injected, 
or taken orally into the human body for treating diseases.  However, when a medicine 
is injected into a human body, it can be rapidly degraded or metabolized, requiring 
repeated injections to maintain the medicine at a therapeutic blood concentration.  
Much research has focused on increasing the medicine’s halflife in the bloodstream.  
One approach has been to shield the medicinal compound by attaching polyethylene 
glycol (PEG) to its surface, a process called PEGylation. 
 
PEG is non toxic, highly soluble in aqueous solutions, readily excretable and has 
extremely low immunogencity and antigencity (Fee 2003; Chowdhury and Wu 2005).  
PEGylation reactions involve the covalent attachment of PEG to an amino acid 
residue on the protein surface.  However PEGylation reactions are notoriously 
difficult to control in terms of where the PEG group is attached on the protein surface 
and how many PEGs may be attached to one protein.  A PEGylation reaction may 
yield many different types of PEGylated protein in terms of attachment site and 
number of PEGs attached, making PEGylated proteins difficult to characterize.  An 
additional problem is isolating a particular type of PEGylated product.   
 
One approach to reduce the diversity of PEGylated protein products from a reaction is 
to perform the reaction inside an axial flow size exclusion column.  Size exclusion 
chromatography separates compounds from a mixture on the basis of size.  Size 
exclusion columns are typically packed with resin particles that have a porous 
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structure.  Molecules too large to enter the resin pores remain in the particle 
interstices and elute from the column faster than smaller molecules that readily diffuse 
into the resin particle pores.  In size exclusion PEGylation reaction protein is applied 
to the top of the column over a set time period, followed by buffer and then by PEG.  
The protein and PEG move down the column as discrete bands at different migration 
rates.  PEG being larger than the protein, moves through the column faster, eventually 
overtaking the protein.  As the PEG overtakes the protein, the two species react, 
producing PEGylated protein which has one or more PEG groups attached.  The 
PEGylation reaction and unreacted products then separate out into distinct bands as 
they continue to migrate through the column.  Extent of PEGylation reaction can be 
controlled by tailoring the reaction conditions such as pulse length of PEG or protein 
and the time in between each pulse. 
 
To obtain optimal conditions for PEGylation reactions within size exclusion column 
requires extensive experimentation, which is expensive for therapeutic proteins.  
Simulating a size exclusion PEGylation reaction using computer models has the 
advantage of reducing the number of experiments required to obtain optimal 
conditions, hence reducing cost.  However little or no research has been presented on 
modeling PEGylation reactions in size exlusion column. 
 
1.2 Research objective 
A size exclusion PEGylation reaction chromatography model was developed by Fee 
(2005).  The objective of this thesis was to maximise the yield of mono-PEGylated 
protein in a simulated size exclusion column and to study the effect of parameters 
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such as reactant concentration, reactant injection length, time between injections, 
reaction rates and volumetric flow rate on mono-PEGylated protein. 
 
1.3 Organization of this thesis 
An overview of PEGylation is presented in Chapter Two, its role in modern drug 
delivery, PEGylation chemistry and examples of PEGylated molecules along with 
their benefits and downstream processing, and size exclusion chromatography is 
introduced. The mathematical model and its solution used for simulating size 
exclusion PEGylation reaction chromatography is detailed in Chapter Three.  
Methods used to obtain model parameters using batch PEGylation experiments are 
described in Chapter Four.  Experimental and model results are presented and 
discussed in Chapter Five and conclusions drawn and recommendations for future 
work are outlined in Chapter Six. 
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2.1 Introduction 
Advances in biochemistry, genetics and biotechnology has led to the proliferation of 
biologically derived pharmaceuticals and therapeutics.  These are routinely injected, 
or taken orally into the human body for treating diseases.  However, when a medicine 
is injected into a human body, it can be rapidly degraded or metabolized, requiring 
repeated injections to maintain the medicine at a therapeutic blood concentration.  
Much research has focused on increasing the medicine’s halflife in the bloodstream.  
One approach has been to shield the medicinal compound by attaching polyethylene 
glycol (PEG) to its surface.  PEG attachment to a protein increases the protein 
molecule size preventing it from being excreted and prolonging its circulation time in 
the blood (Figure 2-1).  Davies and Abuchowsky (1977) produced the first PEGylated 
protein albumin in the 1970s.  Since then, PEGylation has become a popular method 
in medical science and biopharmaceuticals and has been developed to include various 
PEGylation chemistries and conjugation methods (Veronese and Pasut 2005).  PEG is 
non toxic, highly soluble in aqueous solutions, readily excretable and has extremely 
low immunogencity and antigencity (Fee 2003; Chowdhury and Wu 2005).  These 
properties can be imparted to the compound PEG is conjugated with (Fee and Van 
Alstine 2006).  Examples of PEGylated drugs include taxol, camptothecin, 
cisplatinum and doxorubicin (Fee and Van Alstine 2006).  PEGylated antibodies have 
a longer halflife and reduced toxicity and immunogencity than their native 
counterparts with no change in antigen binding ability (Chowdhury and Wu 2005). 
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Figure 2-1: PEGylated protein 
 
2.2 Properties of PEG 
 
Polyethylene glycol polymers are neutral, hydrophilic and soluble in various aqueous 
solutions and organic solvents such as acetone.  PEGs are normally soluble in aqueous 
solution up to 1000C and are reactive at high temperatures.  PEG solubility in aqueous 
solution decreases with increasing temperature and increasing salt concentration (Fee 
and Van Alstine 2006).  
 
Polyethylene glycol molecules consist of n number of repeating ethylene oxide 
subunits, each 44 Da in size.  The average molecular weight of PEG chain is  
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n x 44 Da.  PEG is inert with two terminal hydroxyl groups available for activation or 
conjugation.  PEG can be activated by converting one of the hydroxyl groups to a 
methoxy or alkoxy group.  PEG is available in linear and branched forms.  Two or 
more PEG chains can be joined together with linkers such as lysine or triazine to form 
branched PEG.  Some examples of PEG molecules are shown in Figure 2-2 (Bailon 
and Berthold 1998). 
 
Linear PEG-OH
Linear mPEG-OH
H-(OCH2CH2)n-OH
Ch3-(OCh2CH2)n-OH
Branched mPEG2 mPEG
mPEG
Y
Y  ( CH2 )4 OH
O
or
Long carbon chains
O
OH
 
 
Figure 2-2: Chemical structures of some representative polyethylene glycol (PEG) 
molecules (Bailon and Berthold 1998).  
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As PEGs are high molecular weight polymer chains they tend to increase the viscosity 
of aqueous solutions.  Therefore PEGylated molecules can cause solution foaming 
and can precipitate leading to fouling if passed through a chromatography column.  
Polyethylene glycol is transparent and non-fluorescent (Veronese 2001). 
 
2.3 Improved protein drugs by PEGylation 
 
Polyethylene glycol (PEG)-conjugated proteins belong to a new class of biomolecules 
that are neither proteins nor polymers. In 1977, Abuchowski and colleagues 
demonstrated that Polyethylene glycol conjugated proteins are more effective than 
their corresponding native form (Bailon and Berthold 1998). Now, PEGylation is used 
in several classes of drugs such as in enzymes, cytokines, antibodies and oligomers. 
The main advantages are improved serum half-life reduced immunogencity, low 
toxicity and increased stability towards metabolic enzymes (Veronese and Pasut 
2005).   
 
PEGylation improves the pharmacokinetics properties of the conjugates. A typical 
example is PEGylated α-interferon Pegasys®, retains only 7% of the antiviral activity 
of the native protein and still shows a great improvement in pharmacokinetics than its 
native form (Veronese and Pasut 2005). PEGylated drugs exhibited excellent 
pharmacokinetics properties than the unmodified parent drug by increasing the serum 
half life and residence time of the conjugate by many folds higher than those of 
unmodified drugs (Bailon and Berthold 1998).  
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Some of the polymers that are used as a shield include, polysaccharides, 
polyacrylamide, polyvinyl alcohol, poly(N-vinyl-2-pyrrolidone), polyethylene glycol 
and PEG containing copolymers such as poloxamers, poloxamines and polysorbates. 
PEG and PEG-containing copolymers are the most effective and the most commonly 
used polymers tested to date (Kim, Jeong et al. 2004; Mishra, Webster et al. 2004; 
Owens Iii and Peppas 2006).  
 
In terms of immunogencity and toxicity, PEGylated molecules have shown a reduced 
antibody response and low toxicities in comparison with the unmodified molecule. 
The low molecular weight conjugates enters the extravascular tissues and diffuse back 
in to circulation. The larger the size of the molecule, the slower is the renal clearance 
(Bailon and Berthold 1998).  
 
2.4 PEGylation chemistry 
 
There are several different methods in which a PEG group can be attached to a 
protein.  A common attachment site is the amino group of lysine using acylation or 
alkylation reactions (Zalipsky 1995; Veronese 2001; Veronese and Pasut 2005; Fee 
and Van Alstine 2006).  Different conjugation methods can also be used to target 
thiol, hydroxyl or amide groups of the amino acids on the protein surface using 
several specific linkers or enzymes (Veronese and Pasut 2005). 
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2.4.1 Amino group modification 
 
The amino groups are the first targets in PEGylation since they are the most common 
and exposed groups in proteins. They can be modified using a wide range of 
reactions. (Veronese and Pasut 2005).  Most proteins and antibodies have lysine 
residues with ε-amino groups present on the surface making PEG conjugation 
straightforward (Fee and Van Alstine 2006).  Common reactions used are alkylation 
and acylation.   
 
Alkylating PEGs does not modify the charge of amino residues. In the case of PEG-
aldehyde, a permanent linkage is obtained by forming a shif-base which is reduced by 
carborohydride reduction (Figure 2-3).  Shif-base formation rate is relatively low and 
a PEGylation reaction can take up to a day for the completion of conjugation under 
controlled pH.  In this case the α-amino terminal modification is achieved around pH 
5 (Veronese 2001).  
PEG-O
H
O
+  H2N-R
NH-R
PEG-O
NaCNBH4
 
Figure 2-3: Alkylation of PEG-aldehyde (Veronese 2001) 
 
The majority of acylating PEGs are hydroxylsuccinimilidly esters (-OSu) of 
carboxylated PEGs (Figure 2-4).  The distance between the active ester (-COOSu) and 
the first PEG subunit varies by up to four methylene units.  The distance influences its 
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reactivity towards amino groups and water.  For example, the halflife of PEG-O-CH 2 
–COOSu is 0.75 h and 23 h for PEG-O-CH2-CH2-CH2-COOSu (Veronese 2001). 
 
PEG-O-X-CO-CSu PEG-O-X-CO-NH-R
X= ( -CH2-)n
+  H2N-R
 
Figure 2-4: Activated acyl acids (Veronese 2001) 
 
PEG hydroxyl group activated by chloroformates or carbonylimidazole have different 
acylating chemistries and exhibit lower reaction rates than the –OSu activated PEGs. 
In case of PEG-p-nitrophenlcarbonate or PEG-trichlorophenylcarbonate selectivity of 
conjugation is achieved based on the availability of amino groups (Figure 2-5) 
(Veronese 2001). 
 
O
O
PEG-O
PEG-O O-
O
- NO2
H2N-R+ PEG-O
O
NH-R
Cl
Cl
Cl
 
 
Figure 2-5: PEG-p-nitrophenlcarbonate and PEG-trichlorophenylcarbonate 
(Veronese 2001) 
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Kinster et al. (2002) used pH to control amino modification so that the conjugation 
takes place at the α-amino of the N-terminal instead of α-amino of a lysine residue. 
This was successfully tested on granulocyte colony stimulating factor, available in the 
market as Pegfilgrastim used in the treatment of granulocyte depletion during 
chemotherapy. 
 
2.4.2 Thiol modification 
 
PEGylation by attaching PEG to the cysteine thiol group residue in protein can be 
highly specific because cysteine is rarely present in protein.  Also cysteine is 
hydrophobic it is buried deep inside the protein structure restricting its availability for 
PEGylation.  Hence, thiol modification of proteins for PEG attachment is rapidly 
expanding.  Genetic manipulation allows a cysteine residue to be inserted at specific 
location within the protein’s amino acid sequence.  Another strategy involves 
reducing protein disulphide bridges to expose new thiol groups for PEG attachment 
(Veronese and Pasut 2005; Fee and Van Alstine 2006).  An example of a thiol 
reaction is shown in Figure 2-6 where PEGorthopyridyl-disulphide, an activated 
disulphide, reacts with thiol to yield a stable symmetric disulphide (Veronese 2001; 
Veronese and Pasut 2005).   
 
PEG-S-S--                           +  HS-R                       PEG-S-S-R
N
 
Figure 2-6: Thiol reactive PEG-orthopyridyl-disulphide (Veronese 2001) 
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One example of where thoil modification has been used is human growth factor (G-
CSF).  The non-accessible cysteine 17 was modified by first attaching a low 
molecular weight PEG bearing a thiol reactive group at one end and an azide group at 
the other that could access cysteine because of its low steric hindrance.  A high 
molecular weight PEG was then attached to the azide end of the low molecular weight 
PEG (Veronese and Pasut 2005; Fee and Van Alstine 2006). 
 
Some examples of thiol modified PEG include PEG-Vinyl sulphone (via free 
cysteine), PEG-Iodoacetamide (via free cysteine), PEG-Maleimide (via free cysteine), 
PEG-Orthopyridyl disulphide (via free cysteine), PEG-Hydrazide (via 
oligosaccharides) and PEG-Isocyanate (via alcohol or amino group) (Bailon and 
Berthold 1998).  Examples of PEGs reactive with thiol groups are shown in Table 2-1. 
 
Table 2-1: PEGs reactive towards thiol group (Veronese and Pasut 2005) 
 
Structure Thioreactive PEGs Properties 
 
PEG–
pyridildisulphide 
The most specific towards thiol but 
yields a cleavable linkage by a reducing 
agent also in vivo. 
 
PEG–maleimide 
Gives stable linkage by double bond 
addition but can also react with amines 
at pH >8. 
 
PEG–vinylsulfone 
 
 
PEG–iodo 
acetamide 
Less reactive, not much used. 
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2.4.3 Site specific modification 
 
A common problem with amino acid PEG attachment is that it is not site specific.  For 
example, for reactions involving attaching PEG to lysine residues, PEG will be 
attached anywhere on the protein surface where a lysine residue is.  Therefore a 
PEGylation reaction may produce a mixture of PEGylated products with one or more 
PEG groups attached and with different attachment sites.  In addition, the attachment 
site may be in the active site of a protein reducing or eliminating its activity.  Isolating 
one particular type of PEGylated product from a mixture becomes formidable task.  
This can be overcome using site specific amino modification, of which an example 
was given in the section on thiol modification.   Site specific amino modification 
helps in the purification and characterization of the PEGylated product because only 
one type is produced.  It also preserves protein activity in the conjugate (Veronese and 
Pasut 2005).   
 
One method of site specific modification involves amino acid mutagenesis, where 
amino acids with specific functional groups are genetically incorporated in proteins.  
Deiters et al. (2004) produced a selectively PEGylated protein by attaching an alkyne 
derivatized PEG to the azido group of an incorporated para-azidophenylalanine using 
a mild cycloaddition reaction.  They showed that amino acids with alkenyl, iodo and 
keto groups could be incorporated to produce site specific PEGylated proteins with 
good efficiencies and high selectivity.  Other examples of site specific PEGylation 
used N-Hydroxysuccinimide-activated esters (amide bond), PEG-Epoxide (alkyl 
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bond), PEG-Carbonyl imidazole (urethane bond), PEG-Tresylate (alkyl bond) and 
PEG-Aldehyde (N-terminus, Shiff’s base) (Bailon and Berthold 1998).  
 
2.4.4 Reversible PEGylation 
 
Unlike larger proteins, PEGylation often inactivates smaller peptides because PEG 
attachment is more likely to occur within the peptide’s active site.  Reversible 
PEGylation can be used to preserve protein activity by performing the reaction with 
an inhibitor, a substrate, or ligand specific for the macromolecule present, which 
protects the active site from PEGylation.  In Figure 2-7, the protein’s (E) active site is 
protected from PEGylation by attaching it to a ligand such as a substrate or an 
inhibitor (L) which is linked to an insoluble matrix (Veronese 2001; Veronese and 
Pasut 2005). 
 
 
 
Figure 2-7: Reversible PEGylation. 
 
Salmaso et al (2005) found that small molecular weight PEGs were able to reach the 
active site despite using a protective agent, while more efficient protection was 
achieved when large PEG molecules were used for conjugation. 
 
Literature Review  17 
Shechter et al. (2005) developed a reversibly PEGylated peptide, active PEG40-FMS-
PYY3-36, derived by coupling PYY3-36 with 40 kDa PEG through a spontaneously 
cleavable linker. PEG40-FMS-PYY3-36 half-life was 24 hours, 8 times larger than 
unmodified PYY3-36.  Reversible PEGylation was the only approach successful in case 
of PYY3-36, whereas acetylation and irreversible PEGylation rendered it inactive.   
 
Salmaso et al. (2005) demonstrated that the reversible PEGylation of biotinylated 
antibodies prevented the binding in the vicinity of active site and maintained high 
biological activity.  
 
2.5 Factors affecting PEGylated conjugate behaviour  
 
2.5.1 Site of conjugation and number of polymers attached 
 
The site at which conjugation takes place and the number of polymer chains attached 
plays an important role in determining the characteristics of PEGylated proteins (Fee 
2003; Fee and Van Alstine 2006). In some cases the desired pharmaceutical properties 
can be achieved by addition of only one polymer molecule, for example, 
monoPEGylated interferon, but in other cases extensive PEGylation is required, up to 
2-3 (20-60 kDa) polymer molecules (Bailon and Berthold 1998; Veronese 2001). 
 
The attachment of PEG to proteins can be done in three different ways  
• A single large PEG at a single site 
• A branched PEG at a single site  
• Several small chains at multiple site (monoPEG- one PEG chain, diPEG- two 
PEG chains, triPEG- three PEG chains.. etc) 
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The uni-site PEGylated proteins usually prove to have higher activity since the chance 
of binding at the receptor domains is low, multiple attachment of PEGs may result in 
partial or complete loss of bioactivity (Bailon and Berthold 1998).  
 
The advantage of having a mixture of PEGylated conjugates leads to an expected 
overlapping bioactivity due to various absorption rates is shown in the Figure 2-8. The 
rate of absorption and receptor saturation increases with the degree of PEGylation 
(Bailon and Berthold 1998). 
 
 
 
Figure 2-8: Overlapping bioactivities of components of a polyethylene glycol (PEG) 
conjugate mixture (Bailon and Berthold 1998). 
 
The growth hormone-releasing factor (GRF) (1-29) has three primary amino groups, 
N-terminal, Lys19 and Lys21 to which a PEG group can be attached. The PEGylated 
GRF (1-29) showed different biological activity depending on the amino group where 
the PEG is attached. Youn et al. (2004) separated seven PEG conjugated GRF (1-29) 
(three mono-, three di- and tri-PEGylated GRF (1-29)) by RP-HPLC in a single run, 
with high resolution. The conjugates were then analyzed using MALSI-TOF-MS 
followed by proteolytic digestion.  
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Ton et al. (2005) used dialysis and FPLC to obtain pure mPEG-CPA conjugates with 
specific number of mPEG chains. The dialysis step removed all low molecular 
impurities, including free PEG, making it easy for fractionation.  
 
Tattini et al. (2005) observed that the modification of BSA-PEG in a ratio of (4:1) 
showed a lower degree of structural alterations and lower variation on the 
physiochemical characteristics in comparison with BSA-PEG (2:1).  
 
2.5.2 Size of PEG 
 
Fee and Alstine (2004) suggested that the viscosity radius of a tetra-PEGylated 
molecule with 5 kDa PEG is equivalent to the one which results from mono-
PEGylation with a 20 kDa PEG as measured by (SEC) chromatography. The latter is 
the more effective that the first, since the activity of native protein decreases with 
increased number of attachments. The direct relationship between PEG mass and the 
in-vitro activity are illustrated in the Figure 2-9 (Bailon and Berthold 1998).  
 
Figure 2-9: In vitro and in vivo biological activities as a function of polyethylene 
glycol (PEG) mass (Bailon and Berthold 1998). Circles are the cell culture assay 
uptake and triangles are the in-vivo cell proliferation. 
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As the PEG size increases of a molecule, its distribution through the animal or human 
body decreases.  One example is PEGylation of avidin, a toxic protein found in egg 
white.  Avidin is a xenoprotein processing poor pharmacokinetics and immunological 
properties.  Salmaso et al (2005) found that conjugating avidin with 5 kDa PEG 
reduced the avidin distribution and localized it to the liver and kidney, whereas, the 
20kDa conjugate was confined to the blood stream.  They showed that the conjugation 
of high polymer mass on protein surface suppressed avidin immunogencity and 
antigencity regardless of the polymer size and shape used.  
 
2.5.3 Stabilizing agents 
 
Hinrichs et al (2006), illustrates that various PEGylated nanoparticles can be 
stabilized by oligosaccharides, which are compatible with PEG. For example, inulin 
was able to prevent full aggregation of DOTA/DOPE liposomes, EPC/Chol 
liposomes, DOTAP/DOPE lioplexes and PEI polyplexes during freezing thawing or 
freeze drying, irrespective of the degree of PEGylation of these nanoparticles. 
 
2.5.4 Molecular flexibility 
 
The polymer should have molecular flexibility, since rigid molecules lack in 
significant radius of gyration (Rg) resulting in poor camouflaging of membrane 
antigens. Hence, Rg depends on the intra-chain mobility and lies close to its linear 
length (L) of the rigid polymer. The flexible linear PEG molecules have high Rg and 
provide more protection than a rigid linear PEG (Figure 2-10) (Scott and Chen 2004).  
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Figure 2-10: Rigid Linear Molecule and Flexible Linear Molecule (Scott and Chen 
2004). 
 
2.5.5 Conditions affecting PEGylation reactions 
 
Usually, the cost of native pure protein used in PEGylation is very high. Hence, 
reaction extent and specificity are critical objectives (Fee and Van Alstine 2006).  The 
degree of PEGylation is strongly influenced by coupling conditions such as buffer pH, 
protein to PEG molar ratio, reaction duration, temperature and reaction stoicheometry 
(Bailon and Berthold 1998).  
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pH can change in the PEGylation reaction mixture due to PEG reaction with amino 
groups of proteins and fast aqueous hydrolysis of PEG, altering reaction kinetics. 
Yun, Yang et al. (2005) were able to control pH and reduce PEG hydrolysis by 
mixing SCM-PEG (succinimidyl carboxymethyl-mPEG5000) with sodium tetraborate 
to make a small dense PEG-pellet.  They found that the aqueous hydrolysis amount of 
SCM-PEG was decreased and the fluctuation of pH was controlled by simultaneous 
release of sodium tetraborate from the PEG-pellet, and that a greater degree of 
modification compared to the traditional PEGylation technique. 
 
PEGylation conditions can be controlled using reaction engineering, increasing the 
yield and minimizing cost.  Batch processing is the most common and the easiest 
method for PEGylation, the other being unidirectional and single-pass processes such 
as in chromatography column (Bailon and Berthold 1998).  
 
2.6 Limitations and drawbacks in the use of PEG 
 
Polyethylene glycol is polydisperse, i.e. it a batch of PEG consists of a mixture of 
molecules whose chain lengths form a Gaussian distribution.  This can affect the 
conjugate biological properties, mainly immunogencity and circulation half-life, for 
example in low molecular weight drugs such as peptides, oligomers and antibodies.  
Improvements in PEG production has resulted in PEGs that have less variation in 
chain length (Veronese and Pasut 2005). 
 
Another concern of using PEG is excretion from the human body.  Large PEG 
molecules tend to accumulate in the liver and spleen leading to macromolecular 
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syndrome and other toxic effects (Owens Iii and Peppas 2006).  Also the high water 
co-ordination of the PEG molecule increases its hydrodynamic volume up to 3-5 
times, which may prevent it from being excreted by the kidneys.  The kidney retains 
molecules greater than 30 kDa in size.  However, PEG chain length may be reduced 
for example by enzymes such as cytochrome (Veronese and Pasut 2005).   
 
The loss of biological activity is one of the main drawbacks. For example, PEGylated 
α-interferon Pegasys® retains only 7% of the antiviral activity (Veronese and Pasut 
2005).   In addition PEG is non-detectable due to its transparent and non-fluorescent 
properties and moreover does not release products easy to quantify upon hydrolysis 
(Veronese 2001).  
 
2.7 Batch PEGylation 
 
In case of batch wise PEGylation, a heterogeneous product mixture of unreacted 
fuctionalized PEG, unreacted native protein, some by-products due to hydrolysis and 
PEGylated proteins (species) with a range of PEGylation sites and extent of 
conjugation is obtained depending on the reaction conditions. For example, 
succinimidyl-propionic-acid-PEG (PEG-SPA) is readily hydrolysed in water to yield 
N-hydroxysuccinimide and some unreactive PEG residues affecting the reaction 
kinetics adding to the complexity for processing and purification. In case of amino-
activated PEGs, hydrolysis is accompanied by aminolysis, hence a molar excess of 
PEG to protein ratio is very important, and 50:1 PEG to protein ratio may be used 
(Fee and Van Alstine 2006).  
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The other by-products of PEGylation may also consist of low quantities of cross-
linked conjugates, considered significant in products intended for therapy.  Hence 
mono-methoxy PEG (mPEG-x) reagents are used to avoid cross-linking (Fee and Van 
Alstine 2006).  
 
The main disadvantage of the batch process is that the reactants, products and the by-
products are mixed and need to be separated after the completion of the reaction. In 
the unpublished work by Fee, mono-PEGylated proteins are yielded using a fed-batch 
process; were small quantities of PEG is added to a large excess of proteins. In this 
case, a partition is required to constantly remove PEGylated proteins from the reactor 
to avoid multiple PEGylation, once an appreciable amount of PEGylated protein is 
accumulated. This method can only control the extent of PEGylation at the cost of 
low protein conversion (Fee and Van Alstine 2006).  
 
This is of the great concern for proteins PEGylated for the pharmaceutical use, but is 
of less concern for other types of PEGylated molecules used for miscellaneous 
purposes, example, catalysis, pesticides, detergents etc (Fee and Van Alstine 2006).   
 
2.8 Packed bed process 
 
Thus, the bio-separation or purification based on the size of molecules, surface charge 
and hydrophobicity may be successful. Hence, size exclusion reaction 
chromatography, ion-exchange chromatography and reverse phase chromatography 
seems to be the best suited or commonly used methods (Fee and Van Alstine 2006; 
Owens Iii and Peppas 2006). 
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The “on column” or packed bed process is being used in attempt to influence both the 
site and extent of conjugation, example, oligopeptide PEGylation. This method is 
found to be quite useful in case of smaller molecular weight substances. This is done 
by; immobilizing the proteins to the solid phase in the column; the reactants and by-
products are washed in the mobile phase giving partial separation followed by elution 
of products. This technique was used by Monkarsh et al. 1997 to PEGylate α-
interferon. The native protein was bound to the ion exchanger and PEG was then 
passed through the column. Some attempts have been made to achieve more activated 
conjugates using the same process, where the active site of protein is held towards the 
solid-phase interface preventing conjugation occurring at the active site (Fee and Van 
Alstine 2006).  
 
In 2003, Fee used size exclusion reaction chromatography (SERC) to exploit the 
differing linear velocities of the species of differing sizes to control the reaction 
extent. This was done by injecting a single pulse of protein and PEG, lowest 
molecular size first since the larger reactants with higher linear velocity catches up 
with the smaller ones forming a moving reaction zone and at the same time separation 
of the species in a single unit operation aiming towards low cost of production. This 
approach is useful for therapeutic proteins less than 20 kDa (Fee and Van Alstine 
2006).  
 
2.9 Purification engineering 
 
The general purification or bio-separation strategy is based on few important factors 
such as, molecular size for membrane separations or size exclusion reaction 
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chromatography, its iso- electric point and surface charge distribution for ion-
exchange chromatography and hydrophobicity for hydrophobic interaction 
chromatography (Fee and Van Alstine 2006). 
 
PEGylation of any bio-molecule gives rise to two basic types of purification 
challenge, the first being separation of the target PEG-biomolecules from other 
reaction products and the second is the sub-fractionation on the basis of positional 
isomerism (Fee and Van Alstine 2006).  
 
Fee and Alstine (2006) designed a table showing PEGylated protein processing 
consisting of proteins with different molecular weights with the conjugation methods 
used for PEGylation and purification steps. The summary of the common conjugation 
methods are listed below 
• Succinimidyl propionate (18%) 
• N-hydroxy succinimide (18%) 
• Succinimide carbonate (16%) 
• Aldehyde (12%) 
• Maleimide (8%) 
• Dithiopyridyl (8%) 
Common purification methods used are: 
• Size exclusion (33.75%) 
• Ion exchange (27.5%) 
• Dialysis and Lyophilisation (11.25%) 
• Ultrafiltration (10%) 
• Reverse phase (8.75%) 
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This shows that size exclusion and ion exchange are the most common methods used 
for purification of PEGylated species.  
 
2.9.1 Size-based separations 
 
Size exclusion reaction chromatography can be used to separate PEGylated species 
from other components, given that the SEC column is calibrated in terms of molecular 
size rather than molecular weight, which has shown consistent results for protein and 
PEG standards (Fee and Van Alstine 2006). In 2004, using this technique, Fee and 
Alstine found that the size of PEGylated proteins can be accurately predicted from the 
radius of a hypothetical PEG molecule having the same molecular weight as the total 
conjugated PEG and the native protein radius. The resolution of SEC decreases 
proportionally with the increase in the extent of PEGylation.  
 
Epoxy group of each PEG is said to affect approximately 16 water molecules as 
suggested by various physical studies and proteins on the other hand interacts via 
covalent, hydrogen bond, van der waals and other interactions in pure water, 
significantly affects the structure of the conjugates (Fee and Van Alstine 2006).  
 
The ability to separate PEGylated species from one another, increases with molecular 
weight, but becomes less effective as the extent of PEGylation increases. Fee and 
Alstine (2006), has shown that, only mono- and di-PEGylated species can be 
effectively separated by SEC when a 5 kDa PEG molecule is used and the separation 
becomes more difficult as the ratio of protein to PEG molecular weight increases.  
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The positional isomers of the same PEGylation extent has different biological 
activities, but identical molecular weights and are much more difficult to separate, 
since they have similar physiochemical properties. The studies by Fee and Alstine 
(2006) suggest that the existing SEC media is suitable for separation of PEG-proteins 
from naïve proteins and moderate separation of PEG proteins of differing N.  
 
2.9.2 Charged-based separations 
 
Ion-exchange chromatography is the most important technique used in PEGylation. 
PEG is a neutral polymer, but has a tendency to affect the charge properties of 
proteins in three different ways as noted in the work published by Fee and Alstine 
(2006). In first case, the presence of the PEG conjugate may shield the surface charge 
of a protein, thereby weakening the binding to ion-exchange resins. Secondly, by 
conjugation to amine acid residues that alter their charge nature at certain pH values 
and thirdly, surface localized PEG may hydrogen bond with acid or other groups. Fee 
and Alstine (2006) have given a good explanation on charged-based separation and 
hydrophobicity based separation in their published work.  
 
Monkarsh et al. (1997), where able to separate 11 positional isomers of mono-
PEGylated α-interferon using cat ion exchange chromatography in analytical scale.  
 
Wu et al. (2005), PEGylated human basic fibroblast growth factor (fb-FGF) with 5 
kDa PEG via the cysteine residue to obtain a conjugate with 80% modification and 
retaining 60% of the mitogenic activity which was successfully purified using ion-
exchange chromatography. 
 
Literature Review  29 
Yun et al. (2004) used two consecutive ion exchange chromatography steps to 
successfully separate and purify the PEGylated rhg-CSF. The cation-exchange 
chromatography was first used to separate the PEGylated species from the un-
PEGylated rhg-CSF, followed by anion-exchange chromatography to separate the 
PEGylated species (mono-, di- and tri-PEGylated rhg-CSF) and the excess free PEG. 
 
2.10 FDA approved PEGylated drugs 
 
There are already a few drugs approved by FDA and are available in the market for 
therapeutical applications. Some of the successfully approved PEGylated conjugates 
include PEGylated α-interferons, for use in the treatment of hepatitis C (PEGasys® 
from Hoffman- LaRoche and PEG intron® from Schering-Plough/Enzon), PEGylated 
growth hormone receptor antagonist (PEG Somavert® from Pfizer), PEG-
asparaginase (Oncospar® from Enzon), adenosine deaminase (ADAGEN® from 
Enzon), and granulocyte colony stimulating factor (Neulasta® from Amgen) (Fee and 
Van Alstine 2006). PEGylated α-interferons used for the treatment of hepatitis C, 
PEGasys® from Hoffman- LaRoche and PEG intron® from Schering-Plough/Enzon 
have sales in excess of $ 1 billion per year (Harris and Veronese 2003). 
 
FDA has approved PEGylated aptamers, 28mer oligomer aptanib for the treatment of 
age-related macular degeneration of retina (Veronese and Pasut 2005).  
 
The requirements for the approval of new PEG modified conjugates are more 
stringent and the characterization of each polymer is compulsory, example are α-
interferon conjugates from PEGasys and PEG-Intron, for which all the binding sites in 
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primary sequence were established (Veronese and Pasut 2005). Due to its non-toxicity 
and non-immunogencity, FDA has approved PEG for using as a base in foods, 
cosmetics and pharmaceuticals (Wu, Li et al. 2006).  
 
2.11 Other applications 
 
The three main areas of application of PEG conjugates are 
• PEG ligands in aqueous two phase partitioning 
• Bioreactor use of PEG co factors and PEG catalysts 
• PEG-drug conjugates for controlled delivery of biologically active substance 
(Zalipsky 1995). 
 
The chemotherapy agent L-asparaginase used in the treatment of acute lymphoblastic 
leukemia therapy has two main disadvantages, the need for frequent intramuscular 
injection and a very high rate of allergic reactions. These problems were overcome by 
conjugation with polyethylene glycol. The conjugate was less likely to cause 
hypersensitivity and provided a long duration form of the drug. Thus the initial 
purpose of PEGylation is achieved (Graham 2003).  
 
Scott and Chen (2003), suggested that the covalent modification of cells and tissues 
with methoxypoly(ethylene glycol) (mPEG) can significantly diminish immunologic 
recognition of other allogenic tissues and enhance the induction of tolerance, tested 
for a specialized form of cellular transplantation. They used a chemical linker to 
substitute the terminal hydroxyl group of mPEG polymer for conjugation. Saline 
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injected animals injected with cyclosporine methoxyPEG showed a mean survival 
time of 11 days while the animals injected with unmodified spenocytes was 8 days.  
 
Some of the theoretical and commercial results of PEGylation are shown in Table 2-2.  
Table 2-2: Approved PEG conjugates (Veronese and Pasut 2005) 
PEG conjugates Type of PEGylation 
Year to 
market Disease 
With proteins 
PEG–asparaginase 
(Oncaspar®)  
Random, linear 
PEG 1994 
Acute lymphoblastic 
leukemia 
PEG–adenosine 
deaminase (Adagen®)  
Random, linear 
PEG 1990 
Severe combined 
immunodeficiency disease 
(SCID) 
PEG–interferon α2a 
(Pegasys®)  
Random, branched 
PEG 40 kDa 2002 Hepatitis C 
PEG–interferon α2b 
(PEG–Intron®)  
Random, linear 
PEG 12 kDa 2000 
Hepatitis C and clinical 
trials for cancer, multiple 
sclerosis, HIV/AIDS 
PEG–G-CSF 
(pegfilgrastim, 
Neulasta®)  
Selective, linear 
PEG 20 kDa 2002 
Treating of neutropenia 
during chemotherapy 
PEG–growth hormone 
receptor antagonist 
(Pegvisomant, 
Somavert®)  
Random, linear 
PEG 5 kDa 
(genetic modified 
protein) 
2002 Acromegaly 
With oligonucleotides 
Branched PEG–anti-
VEGF aptamer 
(Pegaptanib, 
Macugen™)  
Selective, 
branched PEG 40 
kDa 
2004 Macular degeneration (age-
related) 
 
Lee et al. (2005), studied that, PEGylation of islets have a dose reducing effect on the 
immunosuppressive medication and synergistically improved the survival time of 
islets in the transplantation site without causing the infiltration of immune cells. 
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Pancreatic islet transplantation is a method of cell therapy used to treat diabetes 
mellitus. The SPA group of mono-methoxy PEG-SPA was bound with the amine 
groups of collagen matrix of the isolated islets. They found that most of the 
transplanted islets were generally rejected within 2 weeks and PEGylated islets 
survived for 100 days in three out of seven rats; the remaining four rats survived 30 
days on the average (Figure 2-11). 
 
 
Figure 2-11:  Histological analysis of transplanted islets (A) unmodified islets 
rejected within 2 weeks, (B) PEGylated islets rejected at day 30, (C, D) PEGylated 
islets survived for 100 days (Lee et al 2006) 
 
Sainathan et al. (2005) showed that the PEGylated Granulocyte-macrophage colony-
stimulating factor (GM-CSF) has a half-life of 48h compared to 6h of un-PEGylated 
GM-CSF. The PEGylation of GM-CSF was carried out at lysine residue. 
 
Acar et al. (2005) developed a novel superparamagnetic iron oxide nanoparticles 
coated with polymerized PEGylated bilayers, were successful in resisting the 
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aggregation after γ-irradiation. The superparamagnetic iron oxide nanoparticles are 
clinically used for magnetic resonance imaging and many other applications such as 
magnetic drug delivery, cell tracking and hyperthermia.  
 
Wang et al (2004) tested the anti-HIV activity and cytotoxicity of the PEGylated TCS 
derivatives to find that, there was a substantial drop in HIV activity with a increased 
half-life up to 17-22 fold but only a small decrease in cytotoxicity.  
 
Antibodies are a fast growing area in pharmaceutical science because of their ability 
to target specific compounds. The first monoclonal antibody (mAb) tested as 
therapeutic in humans was OKT3 in 1986. There are 18 FDA approved monoclonal 
antibodies available in the market and 150 in clinical developments (Chowdhury and 
Wu 2005).  Engineering specific domains of an antibody can alter its properties to a 
great extent. Also, the additional domains can be used to link them with other 
molecules to achieve desired properties providing scope for PEGylation. PEG chains 
are attached to the antibodies mainly to alter the pharmacokinetics and reducing its 
toxicity by altering PI (Chowdhury and Wu 2005). 
 
Chowdhury and Wu (2005) successfully linked PEG to antibodies while completely 
preserving the antigen binding ability. This was achieved by site-specific PEGylation 
using maleimide chemistry.  In the case of scFv-immunotoxin, they introduced a free 
cysteine as a linker for PEG conjugation. PEGylation of this antibody showed an 
increase in the plasma half-life with reducing toxicity and immunogencity with no 
change in antigen binding ability of the antibodies (data unpublished) (Chowdhury 
and Wu 2005).  
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2.12 Conclusion 
 
In this chapter, the chemistry of PEGylation, properties of PEG, factors affecting the 
behavior of PEGylated conjugate, limitations and problems related to PEGylation, 
processes used for PEGylation, purification engineering and other applications of 
PEGylation was reviewed.  Size exclusion reaction chromatography and ion exchange 
chromatography are two promising purification processes used so far in isolating, 
purifying and producing PEGylated compounds.  Size exclusion reaction 
chromatography separates the PEGylated species on the basis of their molecular 
weight and ion exchange chromatography is used for charge based separations. The 
properties of PEG along with the reaction conditions play an important role in 
determining the reaction kinetics, the site and the extent of PEGylation. 
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3.1 Introduction 
 
In a PEGylation reaction performed in an axial flow size exclusion column, protein is 
applied to the top of the column over a set time period, followed by buffer and then by 
activated PEG.  The protein and PEG move down the column as discrete bands at 
different migration rates depending on the species molecular weight.  PEG being 
larger than the protein, moves through the column faster, eventually overtaking the 
protein.  As the PEG overtakes the protein, the two species react, producing 
PEGylated protein which has one or more PEG groups attached.  The PEGylation 
reaction and unreacted products then separate out into distinct bands as they continue 
to migrate through the column.  Continuity equations used to model these reactions 
and product separation in an axial flow size exclusion column are presented in this 
chapter.  The continuity equations were developed by Fee (2005) and solved using the 
finite difference method (Lay 2005). Column dispersion is neglected in the continuity 
equation but is approximated when the model is solved by treating the column as a 
series of well mixed tanks.  PEGylation reaction is modelled as second order.  The 
model allows up to four PEG groups to be attached to a protein and accounts for 
succinic acid hydrolysis from activated PEG.  The model was adapted to simulate 
PEGylation and PEG hydrolysis in a batch stirred tank so rate parameters from stirred 
tank kinetic experiments could be obtained. 
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3.2 PEGylation reaction 
 
In a typical PEGylation reaction, one or more activated PEG groups are attached to an 
amino acid on the target protein surface.  The reaction yields a PEGylated protein 
with n PEG groups and succinic acid.  In modeling this reaction it is assumed that  
• one PEG group is attached at a time at a reaction rate k,  
• reaction rate k is dependent on the number of PEG groups already attached, 
and 
• the reaction is irreversible.  
 PEG.SA + (n)PEG.Protein ( )→ nk  (n+1)PEG.Protein +SA (1) 
The change in molar concentration of PEGylated protein with time is given by 
 ( ) APEGPEGnPnPEGnP CCkt
C
)(
)1(
=
∂
∂ +
- ( ) APEGPEGnPn CCk )1(1 ++  (2) 
Where PEGnPC )(  is the molar concentration of protein with n PEG groups attached 
((n)PEG.Protein in equation 1), t is time (s) and ( )nk  is a second order PEGylation 
rate constant (L/M.s) and APEGC  is the molar concentration of activated PEG 
(PEG.SA in equation 1). 
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The change in unPEGylated protein molar concentration with time is given by 
 ( ) APEGPEGnPnPEGnP CCkt
C
)0(0
)0(
==
=
−=
∂
∂
 (3) 
A mole of PEG attached to protein yields one mole of succinic acid, therefore change 
in succinic acid concentration in a PEGylation reaction is given by 
 ( )∑
−
=
=
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 (4) 
Where SAC  is succinic acid molar concentration and N is the maximum number of 
PEG groups attached to a protein. 
In addition succinic acid will irreversibly dissociate from PEG in the absence of 
protein at a rate hydrk  
 PEG.SA  → hydrk  PEG + SA (5) 
Therefore total change in succinic acid molar concentration is given by 
 ∑
=
+=
∂
∂ N
n
APEGPEGnPnAPEGhydr
SA CCkCk
t
C
1
)(  (6) 
Where hydrk is a first order reaction rate (1/s). 
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The total change in activated PEG and inactivated PEG molar concentration is  
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−
=
−−=
∂
∂ 1
0
)(
N
n
APEGPEGnPnAPEGhydr
APEG CCkCk
t
C
 (7) 
 APEGhydr
IPEG Ck
t
C
=
∂
∂
 (8) 
where IPEGC  is inactivated PEG molar concentration. 
3.3 PEGylation reaction in an axial flow size exclusion 
column 
 
Modeling a PEGylation reaction in an axial flow size exclusion column is complex 
because the model needs to track the concentration of activated PEG ( APEGC ), 
inactivated PEG ( IPEGC ), succinic acid ( SAC ) and protein ( PEGnPC )( ) with 0 to N 
PEG groups attached, with time and distance through the column.  For simplicity it is 
assumed that: 
• Extra-column and intra-column dispersion is negligible 
• Concentration is uniform with radius 
• Flow velocity is uniform with radius and distance through the column 
• The solid and liquid phases are incompressible 
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• The PEGylation reaction is isothermal 
• There is no adsorption of protein, PEG and succinic acid to the solid phase 
• Retention time in the column is a function of available pore and interstitial 
volume which is dependent on the molecular weight of the protein, PEG, 
PEGylated protein and succinic acid. 
The change in concentration of the ith component due to convection is given by 
performing a mass balance on a thin section of height x∆  of an axial flow column of 
radius cr . 
 tQCtQCxKrCxKrC Xxixiavictiavictti ∆−∆+∆=∆ ∆+∆+
22 pipi  (9) 
Where iC  is the i
th
 component concentration, cr  is column radius, aviK  is available 
pore and interstitial volume fraction, and Q  is volumetric flowrate of solution through 
the column. 
Simplifying equation 9 gives 
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=
∆
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 (10) 
Letting t∆  and x∆  approach zero gives 
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To account for change in concentration of the ith component due to reaction a reaction 
term is included 
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Where ( )Rxn
t
Ci
∂
∂
 is given by equations 2, 3, 6, 7 or 8.  For example, the change in 
concentration of a PEGylated protein with n number of PEG groups is 
 ( ) APEGPEGnPn
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 ( ) APEGPEGnPn CCk )1(1 ++−   (13) 
 
3.3.1 Finite difference solution for axial flow size exclusion column 
chromatography 
 
An axial flow column bed is divided into X stages along the axis. Each stage is 
modeled as a well-mixed tank (Figure 3-1).  
Under ideal conditions, the maximum number of stages required can be calculated by  
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pd
LX
⋅
=
16max
 (14) 
where L is the axial bed length and dp is the diameter of the resin particles (Levenspiel 
1993). 
The height (∆x), cross sectional area (Ac), volume of each stage (Ve) and change in 
time (∆t) are given by 
 
X
L
x =∆  (15) 
 
2
cc rA pi=  (16) 
 xAV ce ∆⋅=  (17) 
 
JQ
V
t e
⋅
⋅
=∆ ε  (18) 
where ε  is the packed bed interstitial void fraction.  Normally J, a dimensionless 
parameter for reducing ∆t for each time step, is set to 3, but can be increased if the 
model becomes unstable when change in concentration due to reaction is high giving 
negative concentration values for the time step.  
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Figure 3-1: Axial flow model 
Total time steps T is given by, 
 
t
t
T run
∆
=  (19) 
Where 
 ∑
=
=
stepsJ
j
j
run Q
V
t 1  (20) 
Jsteps is the total number of steps taken in a run and Vi is the volume applied for jth 
step. 
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In finite difference form equation 9 becomes 
 tQCtQCxKrCxKrC txitxiavictxiavictxi ∆−∆+∆=∆ −−−− 1,1,1
2
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,
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Simplifying and substituting in equations 16 and 17, equation 21 becomes 
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Including change in concentration due to reaction in equation 22, the finite difference 
equations for APEGC , IPEGC , SAC , PEGnPC )(  with 0 to 4 PEG groups attached, 
assuming PEGylation of a protein stops once 4 PEGs are attached, are: 
Where   11 +≤< Xx  and 11 +≤< Tt  
UnPEGylated protein (n=0) 
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MonoPEG (n=1) 
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DiPEG (n=2) 
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TriPEG (n=3) 
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TetPEG (n=4) 
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Activated PEG 
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Inactivated PEG 
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Succinic acid 
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For boundary conditions 
 11 +≤≤ Xx  and 1=t  
 0
,
):0( ==
xtPEGNnP
C , 0
,
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 PfeedxtPEGnP CC == ,)0(  (32) 
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 PEGfinishPEGstart ttt ≤≤   and 1=X  
 PEGfeedxtAPEG CC =,  (33) 
PfeedC  and PEGfeedC  are the initial feed concentrations of protein and PEG 
respectively. 
3.3.2 Stirred tank rate kinetic experiments 
 
In modeling PEGylation reactions in stirred tanks, the entire vessel is treated as a well 
mixed tank, i.e. there is no change in concentration with distance (x), and there is no 
net fluid flow in or out of the tank (Q=0).  Therefore equations 23-30 reduce to 
change in concentration over time due to reaction only.  For example, equation 30 for 
succinic acid becomes 
 At 11 +≤< Tt  
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The boundary conditions are 
 At 1=t  
 0):1( == tPEGNnPC , 0=tSAC , 0=tIPEGC   
 PstarttPEGnP
CC =
= )0(   
 PEGstarttAPEG CC =  (35) 
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Where PstartC  and PEGstartC  are the starting protein and PEG concentrations 
respectively.  Total time steps T is obtained from equation (19). 
3.4 Conclusion 
Finite difference models were developed to simulate stirred tank and size exclusion 
chromatography PEGylation of proteins.  Model parameters can be obtained from 
stirred tank rate kinetic experimental data by fitting model curves to experimental 
results.  These parameters can then be used in SEC PEGylation simulations.     
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4.1 Introduction 
 
This chapter presents the methods used for the experiments repeated in this thesis. 
There are two main areas of experimental work: 
 
• Determining the hydrolysis rate of the PEG-SPA 2kDa and 20kDa in a batch 
process. The rate kinetic experiment was carried out in a stirred beaker and the 
samples were tested using size exclusion chromatography. 
• Determining the rate of PEGylation. The reaction was carried out at room 
temperature in a continuously stirred beaker and the analysis was done using 
size exclusion chromatography (AKTAexplor 10 liquid chromatography at 
UV Abs 280nm, Amersham Biosciences, Sweden).  
 
4.2 Reagents 
 
The following reagents where used: 
• Feed proteins: α- Lactalbumin from bovine milk (85% pure by 
polyacrylamide gel electrophoresis (PAGE)), Mr =14.2 kDa, Sigma (St.Louis, 
MO), Bovine serum albumin (BSA) from bovine plasma (98% pure by 
PAGE), Mr =66.7 kDa, Sigma (St.Louis, MO) and β- Lactoglobulin from 
bovine milk (90% pure by PAGE), Mr =36.0 kDa, Sigma (St.Louis, MO). 
• Linear PEG (mPEG-SPA) reagent of Mr 2 kDa and branched PEG reagent of 
Mr 20kDa (Nektar Therapeutics, Huntsville, AL) 
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• Elution buffer: PBS (phosphate buffered saline) made of 7.4 pH, Sigma 
(St.Louis, MO) 
• Polyethylene glycol (PEG) 3120-71,000 Mr size exclusion calibration kits 
(Phenomenex US) 
• Blue Dextran 2000, Mr =2000 kDa, Sigma (St.Louis, MO) 
• 0.1 M HCl (University of Waikato) 
• 0.1% trifluroacetic Acid (TFA) 
 
4.3 Equipment 
 
The equipment used is: 
• AKTAexplorer 10 liquid chromatography system (UV Abs at 280nm), 
Amersham Biosciences, Sweden 
• Superdex 200 HR 10/30 column, Amersham Biosciences, Sweden 
 
4.4 Batch kinetics 
4.4.1 Succinic acid hydrolysis from activated PEG 
 
Batch kinetic experiments of PEG-SPA 2000 were carried out in a continuously 
stirred beaker. The setup consisted of a magnetic stirrer, 25ml beaker and 1ml 
sampling bottles. 10 mg of PEG-SPA 2000 was added to 10 ml PBS buffer (7.4 pH) 
in a constantly stirred beaker and 1 ml of the sample is collected from the beaker at 
desired time intervals and acidified with two drops of 0.1 M HCl to stop the 
hydrolysis. The same procedure was repeated for the 20 kDa PEG. The samples for 
linear and branched PEG were analyzed using an AKTA10 30cm long size exclusion 
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column (Superdex 200 HR 10/30 column, Amersham Biosciences, Sweden), and 
succinic acid peaks were measured using an inline spectrophotometer set at an 
absorbance of 280nm.  The peaks were analyzed using AKTA software to obtain peak 
area, peak height and retention volume. The peak area was then used to calculate the 
mass and concentration of succinic acid.  The change in concentration of hydrolysed 
PEG’s was plotted against time to determine the rate of hydrolysis.  
 
4.4.2 Batch PEGylation 
 
In experiments done by Li (2004) 10mg α-lactalbumin was PEGylated with 40mg 
20kDa linear polyethylene glycol in a stirred beaker containing 10ml PBS buffer (pH 
7.4).  Samples were taken at desired time intervals and the reaction stopped in the 
sample by adding 2 drops of 1M HCl.  The samples were analyzed using an AKTA10 
30cm long size exclusion column (Superdex 200 HR 10/30 column, Amersham 
Biosciences, Sweden), and protein peaks were measured using an inline 
spectrophotometer set at an absorbance of 280nm.  The peaks were integrated using 
AKTA software to obtain peak area, which was then used to calculate mass by 
comparing data to a calibration curve.  The change in mass over time of the different 
protein peaks was used to determine reaction rates.  The rate parameters from this 
analysis are used in the axial flow size exclusion reaction model simulations.  (see 
chapter 3 modeling). 
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4.5 Column calibration 
 
The Superdex2000 size exclusion column was calibrated using 40 µL of 20 mg/mL 
proteins from the calibration kit, 1mg/mL blue detran, 1.0 mg/mL ferritin, or 
10mg/mL of each mPEG. All solutions were made in PBS buffer at pH 7.4 and run at 
0.5 mL/min. samples were automatically injected in to the size exclusion column. The 
standards were run after every 3-4 months. 
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5.1 Introduction 
 
Batch PEG succinic acid hydrolysis results and analysis of batch PEGylation of α-
lactalbumin data and size exclusion PEGylation reaction chromatography model 
simulations are presented in this chapter.  Models presented in Chapter 3 are used to 
fit experimental data to obtain model parameters.  The effect of reaction parameters 
such as timing, length and concentration of PEG and protein injections, reaction rates, 
and model resolution are explored. 
  
5.2 Batch PEG hydrolysis 
 
Results of batch PEG succinic acid hydrolysis experiments are shown in Figures 5-1 
and 5-2 and Tables 5-1 to 5-4.  Free succinic acid concentration increased with time 
until after 100 minutes when all of the succinic acid had been hydrolysed from the 
PEG.  A high degree of succinic acid hydrolysis was observed early in both 
experiments, which suggested either a systematic experimental error because the 
results for both 2kDa PEG and 20 kDa PEG were consistent, or that succinic acid had 
already hydrolyzed from the PEG prior to the start of both experiments.  A systematic 
experimental error due to chromatographic analysis could not be confirmed because a 
calibration curve of succinic acid concentration versus peak height was not done.  
Succinic acid hydrolysis prior to the start of the experiments could possibly have been 
identified by introducing the activated PEG to an acidified solution buffer and 
immediately analyzing the solution for free succinic acid.  The results for the linear 
and branched PEG were almost identical, demonstrating that the method was 
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repeatable despite using two different types and sized PEG.  Therefore the mechanism 
for hydrolysis of succinic acid from PEG is unaffected by the PEG size.  
 
A good model fit was obtained when succinic acid hydrolysis that occurred prior to 
the experiment had been taken into account, demonstrating that a first order model 
was suitable for simulation succinic acid hydrolysis from activated PEG. 
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Figure 5-1: hydrolysis of 2kDa linear PEG 
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Figure 5-2: hydrolysis of 20kDa branched PEG 
 
Table 5-1: Results for the hydrolysis of 2kDa linear PEG 
 
Time (min) 
Retention 
volume (ml) 
Peak height 
(mAU) 
Peak area 
(mAU*ml) 
Mass of succinic 
acid (mg) 
10 20.44 4.831 3.539 0.00045 
20 20.46 5.821 3.802 0.00048 
30 20.46 6.126 4.133 0.00053 
40 20.46 5.705 4.098 0.00052 
50 20.46 6.368 4.250 0.00054 
60 20.44 6.665 4.534 0.00058 
90 20.44 6.499 4.480 0.00057 
120 20.44 6.578 4.483 0.00057 
150 20.45 6.498 4.616 0.00059 
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Table 5-2: Results for the hydrolysis of 20kDa branched PEG 
 
Time 
(min) 
Retention 
volume (ml) 
Peak height 
(mAU) 
Peak area 
(mAU*ml) 
Mass of succinic 
acid  (mg) 
2 20.42 53.521 37.749 0.00049 
5 20.42 56.311 39.924 0.00051 
10 20.42 55.412 39.558 0.00051 
15 20.42 59.389 42.148 0.00054 
20 20.4 59.901 42.641 0.00055 
40 20.41 59.433 42.540 0.00055 
60 20.41 61.339 43.691 0.00056 
120 20.4 63.7 45.587 0.00059 
 
Table 5-3: Calculated moles of succinic acid and activated PEG remaining for 2kDa 
PEG. 
 
Time (min) 
Moles SA in 1 ml 
sample 
Moles activated 
PEG remaining 
10 3.62E-07 1.10E-07 
20 3.89E-07 8.32E-08 
30 4.23E-07 4.94E-08 
40 4.19E-07 5.30E-08 
50 4.35E-07 3.75E-08 
60 4.64E-07 8.45E-09 
90 4.58E-07 1.39E-08 
120 4.58E-07 1.36E-08 
150 4.72E-07 0.00E+00 
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Table 5-4: Calculated moles of succinic acid and activated PEG remaining for 20kDa 
PEG. 
 
Time (min) 
Moles SA in 1 
ml sample 
Moles 
activated PEG 
remaining 
2 4.12E-07 8.55E-08 
5 4.35E-07 6.18E-08 
10 4.31E-07 6.57E-08 
15 4.60E-07 3.75E-08 
20 4.65E-07 3.21E-08 
40 4.64E-07 3.32E-08 
60 4.76E-07 2.07E-08 
120 4.97E-07 0.00E+00 
 
5.2.1 Calculations for the mass of succinic acid  
 
The following calculations were done to obtain the mass and molar concentration of 
succinic acid and PEG. 
 
For 2kDa linear PEG: 
 
Molecular weight of succinic acid = 118.09 g/mol 
Molecular weight of 2kDa PEG = 2000 g/mol 
Molecular weight of activated PEG = 2118.09 g/mol 
Mass of 2kDa PEG used for hydrolysis in 10ml PBS buffer = 10mg 
Concentration of PEG = 1mg/ml = 0.001g/ml 
 
Moles of activated PEG per ml = Concentration of PEG / Molecular weight of 
activated PEG = 0.001/ 2118.09 = 4.721x 10-7 moles/ml 
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Mass of succinic acid = moles of activated PEG per ml x molecular weight of succinic 
acid = 4.721x 10-7 x 118.09 = 5.575 x 10-5 gm/ml 
Therefore total mass of succinic acid in 10 ml PBS buffer = 0.0005575 g 
 
Maximum peak area = 4.616 
Total mass of succinic acid = 0.0005575 g 
 
Mass of succinic acid per unit area = total mass of succinic acid / maximum peak area 
= 0.0005575 / 4.616 = 0.000127 mg 
Therefore mass of succinic acid is given by, 
Mass of succinic acid = mass of succinic acid per unit area x peak area of the sample 
 
For 20kDa branched PEG: 
 
Molecular weight of succinic acid = 118.09 g/mol 
Molecular weight of 20kDa PEG = 20000 g/mol 
Molecular weight of activated PEG = 20118.09 g/mol 
Mass of 20kDa PEG used for hydrolysis in 10ml PBS buffer = 100.1mg 
Concentration of PEG = 10mg/ml = 0.01g/ml 
 
Moles of activated PEG per ml = Concentration of PEG / Molecular weight of 
activated PEG = 0.01/ 20118.09 = 4.971x 10-7 moles/ml 
Mass of succinic acid = moles of activated PEG per ml x molecular weight of succinic 
acid = 4.971x 10-7 x 118.09 = 5.87 x 10-5 gm/ml 
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Therefore total mass of succinic acid in 10 ml PBS buffer = 0.000587 gm 
 
Maximum peak area = 45.5871 
Total mass of succinic acid = 0.000587 gm 
Mass of succinic acid per unit area = total mass of succinic acid / maximum peak area 
= 0.000587 / 45.5871 = 1.287 x 10-5 mg 
 
Therefore mass of succinic acid is given by, 
Mass of succinic acid = mass of succinic acid per unit area x peak area of the sample 
 
5.2.2 Model parameters for succinic acid hydrolysis from PEG  
The following parameters were used to obtain a good model fit with experimental 
data in Figures 5-1 and 5-2. 
 
For hydrolysis of 2kDa linear PEG: 
Starting activated linear PEG = 1.5 x 10-7 mol/ml 
Starting succinic acid = 3.25 x 10-7 mol/ml  
Rate of hydrolysis of 2kDa PEG khydrolysis = 0.03 1/min 
min1=∆t  
 
For hydrolysis of 20kDa branched PEG: 
Starting activated branched PEG = 9.00 x 10-8 mol/ml 
Starting succinic acid = 4.05 x 10-7 mol/ml  
Rate of hydrolysis of 2kDa PEG khydrolysis = 0.04 1/min 
min1=∆t  
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5.3 Rate kinetics for PEGylation reaction 
 
The results for the batch PEGylation of a-lactalbumin with 20kDa PEG is shown in 
Figure 5-3, and Table 5-5.  Native protein concentration drops rapidly in the first 5 to 
10 minutes after which the rate of decrease slows.  MonoPEG increases rapidly in the 
first 5 minutes after which it decreases due to additional PEG groups being attached in 
the PEGylation reaction.  DiPEG peaks around 30 minutes whereas TriPEG continues 
to increase over time.  These results show that one or two PEG groups can be 
relatively attached easily as is demonstrated by the MonoPEG and DiPEG peaks in 
the first five minutes.  TriPEG formation occurs at a much slower rate either because 
all available surface lysine has been used for PEG attachment, in which case, the 
activated PEG must somehow attach to lysine residues within the protein, or because 
the PEG groups form a shield around the protein restricting further PEG attachment.  
Values listed in Table 5-5 are used to determine the rate of formation of monoPEG.  
 
Table 5-5: The values obtained from the unpublished work by Li (2004) 
 
Reaction time 
(min) 
Protein 
concentration 
(mg/ml) 
MonoPEG 
concentration 
(mg/ml) 
DiPEG 
concentration 
(mg/ml) 
TriPEG 
concentration 
(mg/ml) 
5 0.17 0.49 0.31 0.011 
10 0.061 0.33 0.30 0.094 
30 0.007 0.15 0.37 0.380 
60 0 0.03 0.18 0.497 
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Figure 5-3:  PEGylated and native a-lactalbumin concentrations with time in batch 
PEGylation reaction (Li 2004). 
 
The initial reaction between the PEG moles and the number of lysine moles is 
assumed to be irreversible because the PEGylation reaction involves a covalent 
attachment of activated PEG to a lysine residue.  The reaction is assumed to be second 
order due to involvement of two reacting species, PEG and protein.  Therefore from 
Chapter 3 the reaction is, 
 
PEG.SPA + (n)PEG.Protein ( )→ nk  (n+1)PEG.Protein +SA  
 
 
 
The rate of reaction is given by, 
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 BAA CCkr ⋅⋅=−   (36) 
where A = PEG.SPA and B=proteins. 
 
Table 5-6: The experimental data and the model values   
 
t (min) Concentration of protein (mg/ml) XA ln[M(1-XA)/M(1-XA)] 
5 0.17 0.83 1.426 
10 0.061 0.94 2.42 
30 0.007 0.993 4.53 
60 0 1.000 6.47 
 
 
Figure 5-4: MonoPEG formation against time. Where, M= molar ratio and XA = 
molar concentration. Test for second order kinetics 
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Figure 5-5: Ditto Test for second order kinetics, fit is satisfactory 
 
From Figure 5-4, slope is given by, 
 09.0)1( 1 =⋅− kM   (37) 
 
k1 is given by, 
 
 0489.0)184.2(09.0)1(09.01 =−=−= Mk  (38) 
 
Where molar ratio M is given by, 
 
 
BO
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C
C
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Molecular weight of protein= 14.2kDa and PEG= 20 kDa, hence molar concentration 
of protein is given by, 
 
 gmolCAO ⋅
∗
=
10002.14
1
 (40) 
 
Molar concentration of PEG is given by, 
 
 gmolCAO ⋅
∗
=
100020
4
  (41) 
 
Therefore molar ratio M is given by, 
 
 48.2
20
2.14*4
===
BO
AO
C
C
M   (42) 
 
The overall rate equation is given by, 
  
 BAprotein CCr ⋅⋅=− 0489.0   (43) 
 
The first reaction where MonoPEG is formed by attaching PEG to a single protein 
lysine residue is a very fast reaction; therefore Mono PEG concentration peaks around 
5 minutes.  Then it decomposes into Di and Tri PEG by subsequent attachment of 
more PEG molecules to the PEGylated protein.  The formation of Di and TriPEG is 
dependent on the rate of MonoPEG formation assuming that PEG attachment is 
sequential.  This problem was solved by using MATLAB to fit model data to native 
protein and PEGylated protein concentrations.  The order of the Di and TriPEG 
formation was found to be 1.5. 
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Figure 5-6: Reaction rate of MonoPEG Solid line represents model where as points 
represent experimental data.  Where, CM= concentration of monoPEG 
 
Given that the order of the reaction is 1.5, 
 
 
5.1
2 M
M Ck
dt
dC
⋅=
−
 (44) 
 
Integrating equation (44) gives, 
 tk
CC MM
⋅=− 25.0
0
5.0
11
 (45) 
 
The slope from Figure 5-5 is, 
 k2 =0.016 (46) 
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By substituting (46) in equation (44), the rate equation for DiPEG formation is 
 
 
5.1016.0 MM Cdt
dC
rate ⋅=−=   (47) 
 
The overall rate equation is given by, 
 
 PEGmonoPEGPEGoteinmonoPEG CCkCCkr 2Pr1 −=−  (48) 
 
Substituting the values of k1 and k2 in equation (48) gives, 
 
 PEGmonoPEGPEGoteinmonoPEG CCCCr ⋅⋅−⋅⋅=− 0016.00489.0 Pr  (49) 
 
A reasonable model fit in Figure 5-3 was achieved with the data given, which 
indicates the model is suitable.  However goodness of fit could be further verified if 
more experimental data had been obtained. 
 
5.4 Evaluation of results obtained from MatLab 
simulations 
 
5.4.1 Batch model 
 
The following assumptions were made in case of batch model Matlab simulations 
 
• The PEGylation reactions were assumed to be first order  
• Arbitrary values were used for component properties and retarding factors 
 
Results and Discussion  69 
The batch model integrity was tested by doing a mass balances on protein and PEG in 
and out of the simulated column is as shown in the Table 5-7 and Table 5-8.  
 
Constant variables:  
Mass of protein= 20 mg 
Time t=180min 
Volume of the beaker V= 25ml 
Reaction rate of protein k= 0.003 ml/mg.s 
Rate of hydrolysis of PEG hydrolysisk  = 0.001 1/s  
 
The Figure 5-7 shown below is an example of the batch model indicating the changes 
in mass of the reaction components at different feed mass of PEG and also indicates 
the percentage of protein converted in each case.  
 
The mass of mono PEG formed increases in the beginning but starts to decrease as the 
reaction proceeds leading to an increase in higher degree of PEGylated products. A 
similar trend is obtained in case of di PEG and tri PEG but a constant increase can be 
seen in the case of tri PEG. The conversion of protein increases proportionally with 
the mass of the active PEG.  
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Figure 5-7:  mass of the reaction components and percentage of protein converted at 
differing mass of PEG  
 
5.4.2 Axial flow size exclusion reaction model 
 
The MatLab model for the axial flow size exclusion reaction is based on two 
assumptions 
• The PEGylation reactions were assumed to be first order  
• Arbitrary values were used for component properties and retarding factors 
 
The axial flow model integrity was tested by doing a mass balances on protein and 
PEG in and out of the simulated column. This check was carried out by setting the 
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PEGylation reaction rate k at 0mL/mg.s for unPEGylated protein.  The model was 
also rechecked by passing PEG only through the simulated column. The results of the 
test are shown in Table 5-7 and Table 5-8. 
 
1. Assuming k= 0 mL/mg.s 
CPEG=40mg/mL   Cprotein=40mg/mL t=300min   U=0.15 cm/min 
 
Table 5-7: Mass balance at k= 0 mL/mg.s 
  
 
Mass 
(mg) Ratio 
Mass of protein (mg) 47.124 Protein 46.878 0.995 
Mass of PEG (mg) 94.248 PEG 77.314 0.820 
Mass in (mg) 141.37 MonoPEG 0 0 
Mass out (mg) 141.37 DiPEG 0 0 
Concentration of protein (mg/mL) 40 TriPEG 0 0 
Length of Protein pulse (min) 10 TetPEG 0 0 
Concentration of PEG (mg/mL) 40 
Hydrolysed 
PEG 17.112 0.180 
Length of PEG pulse (min) 20 Succinic acid 0.134 0.001 
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2. At zero protein or Cprotein = 0 mg/mL 
CPEG=40mg/mL     t=300min   U=0.15 cm.min 
 
Table 5-8: Mass balance at Cprotein = 0 mg/mL 
  
 
Mass 
(mg) Ratio 
Mass of protein (mg) 0 Protein 0 NaN 
Mass of PEG (mg) 94.248 PEG 77.004 0.820 
Mass in (mg) 94.248 MonoPEG 0 NaN 
Mass out (mg) 94.248 DiPEG 0 NaN 
Concentration of protein 
(mg/mL) 0 TriPEG 0 NaN 
Length of Protein pulse (min) 0 TetPEG 0 NaN 
Concentration of PEG (mg/mL) 40 
Hydrolysed 
PEG 17.112 0.180 
Length of PEG pulse (min) 20 Succinic acid 0.134 0.001 
 
 
At k=0 ml/mg.s and Cprotein= 0 mg/ml the amount of mass fed in is equal to the 
amount of mass out indicating that the model is working properly. All the values 
generated are shown in Table 5-7 and Table 5-8. 
 
Varied protein concentration  
 
The simulations for MatLab model axial flow size exclusion column were carried out 
at different input concentration of proteins. The concentration of PEG.SPA was kept 
constant at 40mg/mL. All the other parameters were kept constant. The results of the 
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studies by varying the concentration are shown in the Figure 5-8 (product mass vs. 
concentration of protein) and Figure 5-9 (product ratio vs. concentration of protein).  
 
Constant variables:  
CPEG =40mg/ml 
Mass of PEG= 47.124 mg 
Superficial velocity U=0.15cm/min 
Time t=300min 
Length of column= 60 cm 
Reaction rate of protein k= 0.003 ml/mg.s 
Protein start and finish = 5 to 15 minutes 
PEG start and finish = 16 to 26 minutes 
 
Table 5-9: The concentration and the mass of protein used for simulations 
 
Concentration of 
protein (mg/mL) Mass of protein (mg) 
5 5.8905 
10 11.781 
15 17.671 
20 23.562 
25 29.452 
30 35.343 
35 41.233 
40 47.124 
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Figure 5-8: product mass vs protein concentration (mg/ml) 
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Figure 5-9: product ratio vs. protein concentration (mg/ml) 
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From the results of the simulation (Figure 5-8 and Figure 5-9), the concentration of 
PEG decreases with increasing concentration of proteins. As the concentration of 
protein is gradually increased, the amount of protein converted gets lower with an 
increase in monoPEG to diPEG ratio. When concentration of protein equals the 
concentration of PEG, a substantial amount of protein is wasted which is undesirable 
since the aim is to achieve cost effectiveness and to increase the yield of mono 
PEGylated protein.   
 
Increasing PEG pulse 
 
The simulations for axial flow size exclusion column was carried out at varied pulse 
length for different concentrations of PEG (CPEG=10mg/mL and CPEG=20mg/mL). 
The concentration of protein is set constant at CProtein= 40mg/mL. The results are 
shown in Figure 5-10 and Figure 5-11.  
 
Constant variables:  
 
Cprotein =40mg/ml 
Mass of protein= 47.124 mg 
Superficial velocity U=0.15cm/min 
Time t=300min 
Length of column= 60 cm 
Reaction rate of protein k= 0.003 ml/mg.s 
Protein start and finish = 5 to 15 minutes 
PEG start = 16 minutes 
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Table 5-10: The pulse length and the mass of PEG used for simulations 
 
Pulse length 
of PEG (min) 
Mass of PEG 
(CPEG=10mg/mL) 
(mg) 
Mass of PEG 
(CPEG=20mg/mL) 
(mg) 
10 11.78 23.56 
20 23.56 ----------- 
30 35.34 70.69 
40 47.12 ---------- 
50 58.91 117.81 
60 70.69 ---------- 
70 82.47 164.93 
90 --------- 212.06 
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Figure 5-10: product mass vs pulse length of PEG (CPEG= 10mg/mL) 
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Figure 5-11: product mass vs pulse length of PEG (CPEG= 20mg/mL) 
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Figure 5-12: product ratio vs PEG pulse length (CPEG= 10mg/mL) 
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Figure 5-13: product ratio vs pulse length of PEG (CPEG= 20mg/mL)   
 
The addition of PEG after 30 minutes does not make any difference to the mass of the 
other species because all the products and the unreacted protein have already moved 
out of the column (Figure 5-12 and Figure 5-13). Hence to increase the time of 
contact between reactants it is suggested to have a longer column or the feed injection 
flow needs to be minimized. The length of the column used to run the model 
simulations was 60cm and the flow rate was set at 0.118 cm3/min. 
 
Table 5-11: The pulse length and the mass of PEG used for simulations 
Pulse length of PEG 
(min) 
Mass of PEG 
(CPEG=40mg/mL) (mg) 
10 47.124 
11 51.836 
12 56.549 
13 61.261 
14 65.973 
20 94.248 
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Figure 5-14: product mass vs pulse length of PEG (CPEG= 40mg/mL)  
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Figure 5-15: product ratio vs pulse length (CPEG= 40mg/mL) 
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From the Figure 5-15, there is a good ratio of monoPEG, diPEG and also good 
conversion of protein. Hence small doses of highly concentrated PEG is more 
effective than longer PEG pulse with low concentrations. In this case equal 
concentrations of PEG and protein is used (CPEG= CProtein= 40mg/mL). 
 
Rate of hydrolysis of PEG 
 
The simulations of axial flow size exclusion column where carried out at different 
khydrolysis to check the affect of rate of hydrolysis of PEG on the PEGylation reactions. 
The results from the simulations are shown in Figure 5-16 and Figure 5-17. 
 
Constant variables:  
 
Cprotein = CPEG = 40mg/ml 
Mass of protein and PEG= 47.124 mg 
Superficial velocity U=0.15cm/min 
Time t=300min 
Length of column= 60 cm 
Reaction rate of protein k= 0.003 ml/mg.s 
Protein start and finish = 5 to 15 minutes 
PEG start and finish = 16 to 26 minutes 
 
From the Figure 5-16 and 5-17, the rate of hydrolysis of PEG does not have a major 
affect on the overall PEGylation reaction. The increase in rate of hydrolysis of PEG 
leads to the formation of hydrolysed PEG with not significant change in the mass of 
other products of PEGylation reaction. In the case of higher hydrolysis rates of PEG, 
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the feed of PEG needs to be increased to see that there is substantial amount of PEG 
for PEGylation to take place. 
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Figure 5-16: product mass vs k hydrolysis 
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Figure 5-17: product ratio vs k hydrolysis 
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Product mass and ratio 
 
The product mass of the components is calculated from the peak areas under the 
chromatogram obtained for each species from the simulated model of the axial flow 
size exclusion column. The product ratio for all the simulations were obtained by 
dividing the mass output of the unreacted protein and the PEGylated proteins by the 
total mass of protein fed in to the simulated axial flow size exclusion column. The 
product ratios for unreacted PEG, hydrolyzed PEG and succinic acid are calculated by 
total mass output of these components divided by the total mass of PEG fed in to the 
simulation model column.  
 
5.4.3 Sample simulation curves 
 
1. Sample curve 
The sample curve is obtained from the simulation of axial flow size exclusion reaction 
model. The variables used to obtain the sample curve (Figure 5-18) are listed below. 
 
Variables  
Cprotein = CPEG = 40mg/ml 
Mass of protein and PEG= 47.124 mg 
Superficial velocity U=0.15cm/min 
Time t=300min 
Length of column= 60 cm 
Reaction rate of protein k= 0.003 ml/mg.s 
Protein start and finish = 5 to 16 minutes 
PEG start and finish = 16 to 26 minutes 
Number of elements the column is divided in to X=round(L./(16.*Dp)) 
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Figure 5-18: sample curve for the simulation of axial flow size exclusion model   
 
2. Variation of PEG pulse 
 
Variables:  
Cprotein = CPEG = 40mg/ml 
Superficial velocity U=0.15cm/min 
Time t=300min 
Time divider J= 3 
Length of column= 60 cm 
Reaction rate of protein k= 0.003 ml/mg.s 
Protein start and finish = 5 to 16 minutes 
PEG start and finish = 16 to 46 minutes 
Number of elements the column is divided in to X=round(L./(16.*Dp)) 
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Figure 5-19: variation of PEG pulse length  
 
In the Figure 5-19 the peak height of PEG and hydrolyzed PEG are much higher 
compared to Figure 5-18 which is a result of increased PEG pulse length.  
 
3. Change in concentration 
 
Variables:  
Cprotein = 40mg/ml 
CPEG =.15mg/ml 
Superficial velocity U=0.15cm/min 
Time t=300min 
Length of column= 60 cm 
Reaction rate of protein k= 0.003 ml/mg.s 
Protein start and finish = 5 to 16 minutes 
PEG start and finish = 16 to 46 minutes 
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Figure 5-20: change in concentration of PEG 
 
In this case the concentration of the PEG is reduced to 15mg/ml from 40mg/ml hence 
the amount of hydrolyzed PEG produced is also low with lower conversion of protein. 
 
4. Change in time step 
 
Variables:  
Cprotein = 40mg/ml 
CPEG =.15mg/ml 
Superficial velocity U=0.15cm/min 
Time t=300min 
Time divider J= 5 
Length of column= 60 cm 
Reaction rate of protein k= 0.003 ml/mg.s 
Protein start and finish = 5 to 16 minutes 
PEG start and finish = 16 to 46 minutes 
Results and Discussion  86 
 
0 50 100 150 200 250 300 350
0
0.5
1
1.5
2
2.5
3
3.5
4
Co
nc
en
tra
tio
n
 
(m
g/
m
l)
Time (min)
 
 
protein
peg
monopeg
dipeg
tripeg
tetpeg
hydrolysed peg
succinic acid
 
Figure 5-21: Change in time steps at J =5 
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Figure 5-22: Change in time steps at J =1 
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The time divider J can also increase or decrease the resolution of the curves. In case 
of Figure 5-21 the resolution is better compared to Figure 5-20. At J=1, is an example 
of poor resolution. 
 
5. Change in k value 
 
Variables:  
 
Cprotein = 40mg/ml 
CPEG =.15mg/ml 
Superficial velocity U=0.15cm/min 
Time t=300min 
Time divider J= 3 
Length of column= 60 cm 
Reaction rate of protein k= 0.006 ml/mg.s 
Protein start and finish = 5 to 16 minutes 
PEG start and finish = 16 to 46 minutes 
Number of elements the column is divided in to X=round(L./(16.*Dp)) 
 
In the Figure 5-23, more protein is PEGylated compared to Figure 5-20 since the rate 
of reaction of protein in this case was increased by two times from k = 0.003 ml/mg.s 
to k = 0.006 ml/mg.s. 
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Figure 5-23: change in rate of reaction of protein 
 
6. Change in rate of hydrolysis of PEG 
 
Variables:  
Cprotein = 40mg/ml 
CPEG =.15mg/ml 
Superficial velocity U=0.15cm/min 
Time t=300min 
Time divider J= 3 
Length of column= 60 cm 
Reaction rate of protein k= 0.006 ml/mg.s 
Rate of hydrolysis of PEG khydrolysis = 0.003 1/s 
Protein start and finish = 5 to 16 minutes 
PEG start and finish = 16 to 46 minutes 
Number of elements the column is divided in to X=round(L./(16.*Dp)) 
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Figure 5-24: change in rate of hydrolysis of PEG 
 
The increase in rate of hydrolysis of PEG rapidly decomposes the active PEG leading 
to lower conversion of proteins (Figure 5-24). Hence, in the case of higher rate of 
hydrolysis of PEG it is better to increase to concentration of PEG to make sure that 
there is adequate amount of active PEG available for PEGylation to take place. 
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7. Change in resolution 
 
Variables:  
Cprotein = 40mg/ml 
CPEG =.15mg/ml 
Superficial velocity U=0.15cm/min 
Time t=300min 
Time divider J= 3 
Length of column= 60 cm 
Reaction rate of protein k= 0.006 ml/mg.s 
Rate of hydrolysis of PEG khydrolysis = 0.003 1/s 
Protein start and finish = 5 to 16 minutes 
PEG start and finish = 16 to 46 minutes 
Number of elements the column is divided in to X=round(L./(64.*Dp)) 
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Figure 5-25: change in resolution at X=round(L./(64.*Dp)) 
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At X=round(L./(8.*Dp)) 
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Figure 5-26: change in resolution at X=round(L./(8.*Dp)) 
 
The column resolution can be easily varied by varying the facto X (Number of 
elements the column is divided in to). Figure 5-25 and Figure 5-26 are the examples 
for the change in resolution. 
 
5.4.4 Discussion from simulation 
 
Controlling product formation is more difficult for batch processes than the axial flow 
size exclusion reaction process.  The separation of products in the latter is much easier. 
In the axial flow model the PEGylated products move down the column quickly 
minimizing the possibility of higher degree of PEGylated products whereas it is hard 
to remove the mono PEGylated products from the batch process.  
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From the results obtained from the axial flow size exclusion column model, the 
suggested method for PEGylation is the introduction of highly concentrated PEG with 
small pulse lengths. This will give a good conversion of protein (Figure 5-27 ). 
Variables 
Cprotein = CPEG = 40mg/ml 
Superficial velocity U=0.15cm/min 
Time t=300min 
Time divider J= 3 
Length of column= 60 cm 
Reaction rate of protein k= 0.003 ml/mg.s 
Protein start and finish = 5 to 16 minutes 
PEG start and finish = 16 to 36 minutes 
Number of elements the column is divided in to X=round(L./(16.*Dp)) 
 
Table 5-12: Mass of reaction components at pulse length of PEG= 20 min 
 
Product 
Mass 
(mg) 
Protein in  47.124 
PEG in 94.248 
Unreacted protein  0.399 
Unreacted PEG  36.797 
MonoPEG 19.858 
Di PEG 7.090 
Tri PEG 0.955 
Tet PEG 0.085 
Hydrolysed PEG 2.708 
Succinic acid 7.607 
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Figure 5-27: Example for the suggested method for PEGylation 
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6.1 General findings 
Size exclusion PEGylation reaction chromatography was investigated using a model 
developed by Fee (2005).  Column dispersion was neglected and the PEGylation 
reaction was modelled as second order.  The model allowed up to four PEG groups to 
be attached to a protein and accounted for succinic acid hydrolysis from activated 
PEG.  The model was adapted to simulate α-lactalbumin PEGylation and succinic 
acid hydrolysis from activated PEG in a batch stirred tank so rate parameters from 
stirred tank kinetic experiments could be obtained and the model verified.  The model 
was solved using finite differences and simulations run in Matlab.  The effect of 
reaction parameters such as timing, length and concentration of PEG and protein 
injection, reaction rates, and model resolution on model simulation results was 
explored. 
 
Succinic acid hydrolysis data showed little difference between using 2kDa and 20kDa 
PEG in reaction rates indicating that the mechanism for succinic acid hydrolysis from 
PEG is unaffected by the PEG size or type.  A high degree of succinic acid hydrolysis 
was observed early in both experiments, which suggested either a systematic 
experimental error or that succinic acid had already hydrolyzed from the PEG prior to 
the beginning of the reaction.  A good model fit was obtained when initial succinic 
acid hydrolysis was accounted for, showing that the model was suitable for simulating 
succinic acid hydrolysis from activated PEG. 
 
Analysis of α-lactalbumin PEGylation results showed that PEGylation after one or 
two PEG groups have been attached is largely sequential.  MonoPEG and DiPEG 
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peaked at 5 minutes followed a second peak for DiPEG at 30 minutes while TriPEG 
was still forming and had not peaked.  Further PEGylation of protein is hindered by 
the presence of attached PEG groups, either because they form a shield preventing 
access of the activated PEG to the surface or that residues used for attachment had 
already been occupied.  Reaction rates for native protein and MonoPEG was 
determined by mathematical analysis using Matlab.  Rates for MonoPEG formation 
were faster than DiPEG formation assuming PEG attachment was sequential.  Rates 
obtained were used in size exclusion PEGylation reaction simulations.   
 
In the simulations it was found that controlling product formation was more difficult 
for the batch process than the axial flow size exclusion reaction process.  In the size 
exclusion PEGylation simulations it was found that increasing protein concentration 
increased MonoPEG concentrations and increased the ratio of MonoPEG to starting 
protein feed concentration.  Increasing PEG pulse length and starting PEG 
concentration initially increased MonoPEG concentration and product ratio until all 
protein had been PEGylated at which point MonoPEG concentration the product ratio 
levelled out.  Increasing PEG hydrolysis rates did not affect the amount of MonoPEG 
produced but reduced the activated PEG concentration and increased succinic acid 
concentration.  Optimal conditions for producing MonoPEG were found to be equal 
concentrations of PEG and protein, with the PEG injection length twice as long as the 
protein injection, and the PEG injection done immediately after the protein injection. 
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6.2 Recommendations for future work 
 
The following is recommended for future work: 
 
• Need to identify if succinic acid hydrolysis had occurred prior to batch 
experiments as reduced activated PEG concentration will impact on 
PEGylation reaction reducing yields and affecting fitting of models to data. 
 
• Batch PEGylation reaction experiments should be repeated using larger or 
different types of PEG and different types of protein to investigate if 
PEGylation reaction results are repeatable, to identify any errors in analysis, 
and to determine if one model is suitable for a range of PEGylations reactions. 
 
• Perform experiments to verify the optimum size exclusion PEGylation 
reaction conditions found in the model simulations. 
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Appendix A:  Matlab models 
 
 A.1  Axial flow size exclusion reaction column 
 
 
%Column properties 
  
L=60;    % length of column (cm) 
D=1;    % diameter of column (cm) 
Area=(pi.*D.^2)/4;  % (cm^2)  
V=Area.*L;   % volume (cm^3) 
Dp=0.01;   % particle diameter (cm) 
X=round(L./(16.*Dp)); % number of elements column is divided into 
delx=L./X;   % length of an element (cm) 
Ve=V./X;   % volume of an element (cm^3) 
e=1;    % void fraction 
 
 
%Flowrate 
  
U=0.15;   % superficial velocity (cm/min) 
Q=U.*Area;   % flowrate (cm^3/min) 
 
 
%Time 
  
time=300;   % (min) 
res=(Ve.*0.4)./Q;  % residence time (min) 
J=3;    % time divider 
delt=res./J;   % change in time for a time step 
T=ceil(time./delt);  % total number of time steps 
 
 
%Component properties 
  
k=0.003;   % reaction rate for protein (ml/mg.s) 
k1=0.0025;   % reaction rate for mono PEG (ml/mg.s) 
k2=0.002;   % reaction rate for di PEG (ml/mg.s) 
k3=0.0016;   % reaction rate for tri PEG (ml/mg.s) 
khydr=0.001;   % PEG hydrolysis rate (1/s) [first order] 
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%Retarding factors 
  
Kavc=0.6; 
KavPEG=0.5; 
KavMONO=0.4; 
KavDI=0.3; 
KavTRI=0.25; 
KavQU=0.23; 
Kavshydr=0.9; 
 
 
%Molecular weights 
  
MWpeg=5000;  % (g/mol) 
MWs=50;   % (g/mol) 
 
 
%Starting concentrations 
  
cfeed=40;    %(mg/ml) 
PEGfeed=40;    %(mg/ml) 
MONOfeed=0;  %(mg/ml) 
DIfeed=0;    %(mg/ml) 
TRIfeed=0;   %(mg/ml) 
QUfeed=0;   %(mg/ml) 
 
 
%Boundary conditions 
 
  
cstart=5; 
cfin=15; 
PEGstart=16; 
PEGfin=36; 
 
 
%99 percent pure monopeg protein 
 
%cstart=1; 
%cfin=9; 
%PEGstart=10; 
%PEGfin=12; 
 
 
%Calculating concentrations  
 
 
for t=1:T+1; 
    for x=1:X+1; 
        c(t,x)=0; 
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        cPEG(t,x)=0; 
        cMONO(t,x)=0; 
        cDI(t,x)=0; 
        cTRI(t,x)=0; 
        cQU(t,x)=0; 
        cPEGhydr(t,x)=0; 
        cshydr(t,x)=0; 
    end 
end 
 
for t=2:T+1; 
    trun(t)=(t-1).*delt; 
    for x=1; 
        if (trun(t)>cstart & trun(t)<=cfin); 
            c(t,x)=cfeed; 
        end 
        if (trun(t)>PEGstart & trun(t)<=PEGfin); 
            cPEG(t,x)=PEGfeed; 
        end 
    end 
end 
  
for t=2:T+1; 
    for x=2:X+1; 
        c(t,x)=c(t-1,x)+(((c(t-1,x-1)-c(t-1,x)).*Q.*delt)./(Ve.*e.*Kavc))-(k.*c(t-
1,x).*cPEG(t-1,x).*delt); 
        cPEG(t,x)=cPEG(t-1,x)+(((cPEG(t-1,x-1)-cPEG(t-
1,x)).*Q.*delt)./(Ve.*e.*KavPEG))-(k.*c(t-1,x).*cPEG(t-1,x).*delt)-(k1.*cPEG(t-
1,x).*cMONO(t-1,x).*delt)-(k2.*cPEG(t-1,x).*cDI(t-1,x).*delt)-(k3.*cPEG(t-
1,x).*cTRI(t-1,x).*delt)-(khydr.*cPEG(t-1,x).*delt); 
        cMONO(t,x)=cMONO(t-1,x)+(((cMONO(t-1,x-1)-cMONO(t-
1,x)).*Q.*delt)./(Ve.*e.*KavMONO))+(k.*c(t-1,x).*cPEG(t-1,x).*delt)-(k1.*cPEG(t-
1,x).*cMONO(t-1,x).*delt); 
        cDI(t,x)=cDI(t-1,x)+(((cDI(t-1,x-1)-cDI(t-
1,x)).*Q.*delt)./(Ve.*e.*KavDI))+(k1.*cPEG(t-1,x).*cMONO(t-1,x).*delt)-
(k2.*cPEG(t-1,x).*cDI(t-1,x).*delt); 
        cTRI(t,x)=cTRI(t-1,x)+(((cTRI(t-1,x-1)-cTRI(t-
1,x)).*Q.*delt)./(Ve.*e.*KavTRI))+(k2.*cPEG(t-1,x).*cDI(t-1,x).*delt)-(k3.*cPEG(t-
1,x).*cTRI(t-1,x).*delt); 
        cQU(t,x)=cQU(t-1,x)+(((cQU(t-1,x-1)-cQU(t-
1,x)).*Q.*delt)./(Ve.*e.*KavQU))+(k3.*cPEG(t-1,x).*cTRI(t-1,x).*delt); 
        cPEGhydr(t,x)=cPEGhydr(t-1,x)+(((cPEGhydr(t-1,x-1)-cPEGhydr(t-
1,x)).*Q.*delt)./(Ve.*e.*KavPEG))+(khydr.*cPEG(t-1,x).*delt); 
        cshydr(t,x)=cshydr(t-1,x)+(((cshydr(t-1,x-1)-cshydr(t-
1,x)).*Q.*delt)./(Ve.*e.*Kavshydr))+(((k1.*cPEG(t-1,x).*cMONO(t-
1,x).*delt)+(k2.*cPEG(t-1,x).*cDI(t-1,x).*delt)+(k3.*cPEG(t-1,x).*cTRI(t-
1,x).*delt)+(khydr.*cPEG(t-1,x).*delt)).*(MWs./(MWs+MWpeg))); 
    end 
end 
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Xgraph=trun(1:T+1); 
Yc=c(1:T+1,X+1); 
YPEG=cPEG(1:T+1,X+1); 
YMONO=cMONO(1:T+1,X+1); 
YDI=cDI(1:T+1,X+1); 
YTRI=cTRI(1:T+1,X+1); 
YQU=cQU(1:T+1,X+1); 
YPEGhydr=cPEGhydr(1:T+1,X+1); 
Yshydr=cshydr(1:T+1,X+1); 
 
   
Mc=mean(Yc).*time.*Q; 
MPEG=mean(YPEG).*time.*Q; 
MMONO=mean(YMONO).*time.*Q; 
MDI=mean(YDI).*time.*Q; 
MTRI=mean(YTRI).*time.*Q; 
MQU=mean(YQU).*time.*Q; 
MPEGhydr=mean(YPEGhydr).*time.*Q; 
Mshydr=mean(Yshydr).*time.*Q; 
  
 
Massout=Mc+MPEG+MMONO+MDI+MTRI+MQU+MPEGhydr+Mshydr; 
Massin=((cfin-cstart).*Q.*cfeed)+((PEGfin-PEGstart).*Q.*PEGfeed); 
  
  
%Figure 
 
 
plot(Xgraph,Yc,Xgraph,YPEG,Xgraph,YMONO,Xgraph,YDI,Xgraph,YTRI,Xgraph,
YQU,Xgraph,YPEGhydr,Xgraph,Yshydr); 
ylabel('Concentration (mg/ml)');  
xlabel('Time (min)'); 
legend('c','peg','monopeg','dipeg','tripeg','tetpeg','hydrolysed peg','succinic acid'); 
 
 
%Purity of Monopeg 
  
  
%Peakstart=input('Peak start? '); 
%Peakfinish=input('Peak finish? '); 
  
%PeakVol=(Peakstart-Peakfinish).*Q; 
  
%Ps=round(Peakstart./delt); 
%Pf=round(Peakfinish./delt); 
  
%cmass=mean(c(Ps:Pf, X+1)).*PeakVol; 
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%PEGmass=mean(cPEG(Ps:Pf, X+1)).*PeakVol; 
%MONOmass=mean(cMONO(Ps:Pf, X+1)).*PeakVol; 
%DImass=mean(cDI(Ps:Pf, X+1)).*PeakVol; 
%TRImass=mean(cTRI(Ps:Pf, X+1)).*PeakVol; 
%QUmass=mean(cQU(Ps:Pf, X+1)).*PeakVol; 
%PEGhydrmass=mean(cPEGhydr(Ps:Pf, X+1)).*PeakVol; 
%shydrmass=mean(cshydr(Ps:Pf, X+1)).*PeakVol; 
  
  
%Masspeak=cmass+PEGmass+MONOmass+DImass+TRImass+QUmass+PEGhydr
mass+shydrmass; 
  
%MONOpurity=MONOmass./Masspeak 
  
  
  
%Save results to a datafile that can be imported into Microsoft Excel 
  
%Ex(1:T+1,1)=Xgraph; 
%Ex(1:T+1,2)=Yc; 
%Ex(1:T+1,3)=YPEG; 
%Ex(1:T+1,4)=YMONO; 
%Ex(1:T+1,5)=YDI; 
%Ex(1:T+1,6)=YTRI; 
%Ex(1:T+1,7)=YQU; 
%Ex(1:T+1,8)=YPEGhydr; 
  
%csvwrite('peg.dat',Ex); 
  
%Ex(1,1)=((cfin-cstart).*Q.*cfeed);   % total mass of feed protein (mg) 
%Ex(2,1)=((PEGfin-PEGstart).*Q.*PEGfeed); % total mass of feed PEG (mg) 
%Ex(3,1)=Massin;   % total mass fed in to the column (mg) 
%Ex(4,1)=Massout;   % total mass of the products (mg) 
%Ex(5,1)=cfeed;   % feed concentration of protein (mg/ml) 
%Ex(6,1)=cfin-cstart;   % pulse length of protein 
%Ex(7,1)=PEGfeed;   % feed concentration of PEG (mg/ml) 
%Ex(8,1)=PEGfin-PEGstart;  % pulse length of PEG 
  
 
%Ex(1,2)=Mc;   % mass of unreacted protein (mg) 
%Ex(2,2)=MPEG;   % mass of unreacted PEG (mg) 
%Ex(3,2)=MMONO;   %  mass of mono PEG (mg) 
%Ex(4,2)=MDI;   % mass of di PEG (mg) 
%Ex(5,2)=MTRI;   % mass of tri PEG (mg) 
%Ex(6,2)=MQU;   % mass of tetra PEG (mg) 
%Ex(7,2)=MPEGhydr;  % mass of hydrolyzed PEG (mg) 
%Ex(8,2)=Mshydr;   % mass of succinic acid (mg) 
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% Product ratio of components  
  
 
%Ex(1,3)=Mc./((cfin-cstart).*Q.*cfeed); 
%Ex(2,3)=MPEG./((PEGfin-PEGstart).*Q.*PEGfeed); 
%Ex(3,3)=MMONO./((cfin-cstart).*Q.*cfeed); 
%Ex(4,3)=MDI./((cfin-cstart).*Q.*cfeed); 
%Ex(5,3)=MTRI./((cfin-cstart).*Q.*cfeed); 
%Ex(6,3)=MQU./((cfin-cstart).*Q.*cfeed); 
%Ex(7,3)=MPEGhydr./((PEGfin-PEGstart).*Q.*PEGfeed); 
%Ex(8,3)=Mshydr./((PEGfin-PEGstart).*Q.*PEGfeed); 
  
%csvwrite('pegmass.dat',Ex); 
 
 
%Doing animation 
  
 
figure; 
 
  
Step=100;    % number of steps for graphing 
  
S=(T+1)./Step; 
  
for x=1:X+1; 
    dist(x)=(x-1).*delx; 
end 
  
for s=1:Step; 
    ts=round(s.*S); 
    AXgraph=dist(1:X+1); 
    AYc=c(ts,1:X+1); 
    AYPEG=cPEG(ts,1:X+1); 
    AYMONO=cMONO(ts,1:X+1); 
    AYDI=cDI(ts,1:X+1); 
    AYTRI=cTRI(ts,1:X+1); 
    AYQU=cQU(ts,1:X+1); 
    AYPEGhydr=cPEGhydr(ts,1:X+1); 
    AYshydr=cshydr(ts,1:X+1); 
    
plot(AXgraph,AYc,AXgraph,AYPEG,AXgraph,AYMONO,AXgraph,AYDI,AXgrap
h,AYTRI,AXgraph,AYQU,AXgraph,AYPEGhydr); 
    axis([0 60 0 50]); 
    ylabel('Concentration (mg/ml)');  
    xlabel('Distance (cm)'); 
    legend('c','peg','monopeg','dipeg','tripeg','tetpeg','hydrolysed peg'); 
    pause(0.1); 
end 
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A.2   Continuous stirred batch model 
 
%Batch simulation model 
 
%Volume of beaker 
  
V=25;    % (ml) 
 
%Time 
  
time=180;   % (min) 
delt=0.01;   % change in time for a time step 
T=ceil(time./delt);  % total number of time steps 
 
%Component properties 
  
k=0.003;   % reaction rate for protein (ml/mg.s) 
k1=0.0025;   % reaction rate for mono PEG (ml/mg.s) 
k2=0.002;   % reaction rate for di PEG (ml/mg.s) 
k3=0.0016;   % reaction rate for tri PEG (ml/mg.s) 
khydr=0.001;   % PEG hydrolysis rate (1/s) [first order] 
%Molecular weights 
  
MWpeg=5000;  % (g/mol) 
MWs=50;   % (g/mol) 
 
 
%Boundry conditions 
 
 
for t=1:T+1; 
    
        c(t)=0; 
        cPEG(t)=0; 
        cMONO(t)=0; 
        cDI(t)=0; 
        cTRI(t)=0; 
        cTET(t)=0; 
        cPEGhydr(t)=0; 
        cshydr(t)=0; 
   
end 
 
 
%Starting concentrations 
  
for t=1; 
    c(t)=20;   % (mg/ml) 
    cPEG(t)=40;   % (mg/ml) 
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    cMONO(t)=0;   % (mg/ml) 
    cDI(t)=0;   % (mg/ml) 
    cTRI(t)=0;   % (mg/ml) 
    cTET(t)=0;   % (mg/ml) 
    cPEGhydr(t)=0;  % (mg/ml) 
    cshydr(t)=0;  % (mg/ml) 
end 
  
 
 
%Calculating concentrations  
 
 
for t=2:T+1; 
        trun(t)=(t-1).*delt; 
        c(t)=c(t-1)-(k.*c(t-1).*cPEG(t-1).*delt); 
        cPEG(t)=cPEG(t-1)-(k.*c(t-1).*cPEG(t-1).*delt)-(k1.*cPEG(t-1).*cMONO(t-
1).*delt)-(k2.*cPEG(t-1).*cDI(t-1).*delt)-(k3.*cPEG(t-1).*cTRI(t-1).*delt)-
(khydr.*cPEG(t-1).*delt); 
        cMONO(t)=cMONO(t-1)+(k.*c(t-1).*cPEG(t-1).*delt)-(k1.*cPEG(t-
1).*cMONO(t-1).*delt); 
        cDI(t)=cDI(t-1)+(k1.*cPEG(t-1).*cMONO(t-1).*delt)-(k2.*cPEG(t-1).*cDI(t-
1).*delt); 
        cTRI(t)=cTRI(t-1)+(k2.*cPEG(t-1).*cDI(t-1).*delt)-(k3.*cPEG(t-1).*cTRI(t-
1).*delt); 
        cTET(t)=cTET(t-1)+(k3.*cPEG(t-1).*cTRI(t-1).*delt); 
        cPEGhydr(t)=cPEGhydr(t-1)+(khydr.*cPEG(t-1).*delt); 
        cshydr(t)=cshydr(t-1)+(((k1.*cPEG(t-1).*cMONO(t-1).*delt)+(k2.*cPEG(t-
1).*cDI(t-1).*delt)+(k3.*cPEG(t-1).*cTRI(t-1).*delt)+(khydr.*cPEG(t-
1).*delt.*(MWs./(MWs+MWpeg))))); 
    
end 
  
Xgraph=trun(1:T+1); 
Yc=c(1:T+1); 
YPEG=cPEG(1:T+1); 
YMONO=cMONO(1:T+1); 
YDI=cDI(1:T+1); 
YTRI=cTRI(1:T+1); 
YTET=cTET(1:T+1); 
YPEGhydr=cPEGhydr(1:T+1); 
Yshydr=cshydr(1:T+1); 
  
  
figure; 
plot(Xgraph,Yc,Xgraph,YPEG,Xgraph,YMONO,Xgraph,YDI,Xgraph,YTRI,Xgraph,
YTET,Xgraph,YPEGhydr,Xgraph,Yshydr); 
ylabel('Concentration (mg/ml)');  
xlabel('Time (min)'); 
legend('c','peg','monopeg','dipeg','tripeg','tetpeg','hydrolysed peg','succinic acid'); 
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% Mass of products 
 
Mc=c(1+T); 
MPEG=cPEG(1+T); 
MMONO=cMONO(1+T); 
MDI=cDI(1+T); 
MTRI=cTRI(1+T); 
MTET=cTET(1+T); 
MPEGhydr=cPEGhydr(1+T); 
Mshydr=cshydr(1+T); 
  
  
%Save results to a datafile that can be imported into Microsoft Excel 
 
Ex(1:T+1,1)=Xgraph; 
Ex(1:T+1,2)=Yc; 
Ex(1:T+1,3)=YPEG; 
Ex(1:T+1,4)=YMONO; 
Ex(1:T+1,5)=YDI; 
Ex(1:T+1,6)=YTRI; 
Ex(1:T+1,7)=YTET; 
Ex(1:T+1,8)=YPEGhydr; 
Ex(1:T+1,9)=Yshydr; 
  
csvwrite('peg.dat',Ex); 
 
 
%Ratio MONOPEG to DIPEG 
  
%R=MMONO./MDI; 
%Conv=(c(1)-c(T+1))./c(1); 
%P=Conv.*100; 
  
%Ex(1,1)=cPEG(1); 
%Ex(2,1)=MPEG; 
%Ex(3,1)=MMONO; 
%Ex(4,1)=MDI; 
%Ex(5,1)=MTRI; 
%Ex(6,1)=MTET; 
%Ex(7,1)=MPEGhydr; 
%Ex(8,1)=Mshydr; 
%Ex(9,1)=Mc; 
%Ex(10,1)=P; 
  
  
%csvwrite('Batch.dat',Ex); 
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Appendix B 
 
Varied protein concentration  
 
Table B-1: results of simulation by varying the concentration of proteins  
 
Concentration 
of protein 
(mg/mL) 5 10 15 20 25 30 35 40 
Protein 0.031 0.102 0.262 0.604 1.280 2.490 4.425 7.185 
PEG 36.828 29.723 23.289 17.585 12.71 8.754 5.747 3.616 
MonoPEG 1.783 3.891 6.303 8.975 11.814 14.662 17.313 19.592 
DiPEG 1.259 2.368 3.298 4.016 4.495 4.73 4.758 4.650 
TriPEG 0.236 0.393 0.483 0.516 0.508 0.475 0.433 0.394 
TetPEG 0.025 0.037 0.040 0.038 0.033 0.029 0.025 0.022 
Hydrolysed 
PEG 1.979 1.706 1.465 1.255 1.076 0.927 0.807 0.711 
Succinic acid 0.966 1.910 2.738 3.312 3.519 3.340 2.871 2.273 
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Table B-2: product ratio of components at varied concentration of proteins 
 
Mass 5 10 15 20 25 30 35 40 
Protein 0.005 0.008 0.014 0.025 0.043 0.070 0.107 0.152 
PEG 0.781 0.630 0.494 0.373 0.269 0.185 0.121 0.076 
MonoPEG 0.302 0.330 0.356 0.380 0.401 0.415 0.420 0.416 
DiPEG 0.214 0.201 0.186 0.170 0.152 0.133 0.115 0.098 
TriPEG 0.040 0.033 0.027 0.022 0.017 0.013 0.010 0.008 
TetPEG 
x10-3 4.4 3.2  2.3 1.6 1.139 0.818 0.61 0.469 
Hydrolysed 
PEG x10-3 42.009 36.212 31.1 26.641 22.843 19.683 17.12 15.093 
Succinic 
acid x10-3 20.498 40.542 58.11 70.285 74.689 70.884 60.92 48.251 
 
Increasing PEG pulse 
 
Table B-3: results of simulations at different PEG pulse length (CPEG= 10mg/mL) 
 
Pulse length 
(min) 10 20 30 40 50 60 70 
Protein 34.067 22.553 14.816 11.822 11.158 11.071 11.063 
PEG 0.131 0.770 4.153 11.956 22.451 33.472 44.368 
MonoPEG 7.920 14.544 18.613 19.966 20.223 20.254 20.257 
DiPEG 0.452 1.207 1.970 2.406 2.526 2.543 2.544 
TriPEG 0.010 0.038 0.081 0.119 0.134 0.136 0.137 
TetPEG x10-3 0.151 0.785 2.072 3.724 4.656 4.862 4.884 
Hydrolysed 
PEG  0.115 0.393 0.830 1.365 1.938 2.508 3.065 
Succinic acid  0.075 0.624 2.112 3.406 3.842 3.911 3.918 
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Table B-4: results of simulations at different PEG pulse length (CPEG= 20mg/mL) 
Pulse 
length 
(min) 10 30 50 70 90 
Protein 23.044 3.0916 2.5256 2.5226 2.5226 
PEG 0.446 22.13 65.982 110.06 139.45 
MonoPEG 13.712 21.953 21.969 21.969 21.969 
DiPEG 1.547 4.886 5.080 5.080 5.080 
TriPEG 0.068 0.426 0.482 0.483 0.483 
 
 
Table B-5: product ratios at different PEG pulse length (CPEG= 10mg/mL) 
Pulse length 
(min) 10 20 30 40 50 60 70 
Protein 0.722 0.478 0.314 0.250 0.236 0.235 0.234 
PEG 0.011 0.032 0.117 0.253 0.381 0.473 0.538 
MonoPEG 0.168 0.308 0.395 0.423 0.429 0.429 0.429 
DiPEG 0.009 0.025 0.041 0.051 0.053 0.054 0.054 
TriPEGx 10-3 0.219 0.823 1.728 2.53 2.846 2.9 2.9 
 
 
Table B-6: product ratios at different PEG pulse length (CPEG= 20mg/mL) 
Pulse 
length 
(min) 10 30 50 70 90 
Protein 0.489 0.065 0.053 0.053 0.053 
PEG 0.018 0.313 0.560 0.667 0.657 
MonoPEG 0.291 0.465 0.466 0.466 0.466 
DiPEG 0.033 0.103 0.107 0.107 0.107 
TriPEG 0.001 0.009 0.010 0.010 0.010 
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Table B-7: results of simulations at different PEG pulse length (CPEG= CProtein= 
40mg/mL) 
 
Mass 10 11 12 13 14 20 
Protein 7.185 5.202 3.698 2.607 1.843 0.398 
PEG 3.616 5.298 7.4503 10.056 13.068 36.797 
MonoPEG 19.592 20.087 20.338 20.413 20.381 19.858 
DiPEG 4.650 5.176 5.641 6.032 6.344 7.089 
TriPEG 0.394 0.467 0.542 0.617 0.688 0.954 
TetPEG 0.022 0.027 0.033 0.039 0.046 0.084 
Hydrolysed 
PEG 0.711 0.862 1.029 1.208 1.399 2.707 
Succinic acid 2.273 3.041 3.843 4.619 5.321 7.607 
 
 
Table B-8: product ratios at different PEG pulse length (CPEG= 40mg/mL) 
 
 
Pulse length 
(min) 10 11 12 13 14 20 
Protein 0.152 0.110 0.078 0.055 0.039 0.008 
PEG 0.076 0.102 0.131 0.164 0.198 0.390 
MonoPEG 0.415 0.426 0.431 0.433 0.432 0.421 
DiPEG 0.098 0.109 0.119 0.128 0.134 0.150 
TriPEG 0.008 0.009 0.011 0.013 0.014 0.020 
TetPEG x10-3 0.469 0.581 0.707 0.846 0.993 1.802 
Hydrolysed 
PEG  0.015 0.016 0.018 0.019 0.021 0.028 
Succinic acid  0.048 0.058 0.068 0.075 0.080 0.080 
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Rate of hydrolysis of PEG 
 
Table B-9: results of simulations at different k hydrolysis 
K hydrolysis (1/s) 0.00025 0.0005 0.001 0.0015 0.002 0.0025 
Protein 0.398 0.443 0.549 0.677 0.830 1.010 
PEG 36.797 34.458 30.18 26.392 23.043 20.089 
MonoPEG 19.858 19.939 20.098 20.253 20.401 20.539 
DiPEG 7.089 7.036 6.923 6.801 6.670 6.532 
TriPEG 0.954 0.933 0.892 0.850 0.808 0.767 
TetPEG 0.085 0.081 0.075 0.068 0.063 0.058 
Hydrolysed PEG 2.707 5.279 10.044 14.349 18.246 21.778 
Succinic acid 7.606 7.498 7.260 6.995 6.706 6.398 
 
 
Table B-10: product ratios at different k hydrolysis of PEG 
K hydrolysis (1/s) 0.00025 0.0005 0.001 0.0015 0.002 0.0025 
Protein 0.008 0.009 0.011 0.014 0.017 0.021 
PEG 0.390 0.365 0.320 0.280 0.244 0.213 
MonoPEG 0.421 0.423 0.426 0.429 0.432 0.435 
DiPEG 0.150 0.149 0.146 0.144 0.141 0.138 
TriPEG 0.020 0.019 0.018 0.018 0.017 0.016 
TetPEG x10-3 1.802 1.729 1.59 1.46 1.34 1.23 
Hydrolysed PEG  0.028 0.056 0.106 0.152 0.193 0.231 
Succinic acid  0.080 0.079 0.077 0.074 0.071 0.067 
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